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Abstract
The crucial role of microRNAs (miRNAs) in cancer pathobiology has driven the
introduction of new drug development approaches such as miRNA inhibition. In order to
advance miRNA-therapeutics, there is a need to develop screening strategies that can
target tumors in a specific way. Small molecule inhibitors represent an attractive approach
to pursue this. However, the absence of molecular structures for most of the miRNAs
makes it very difficult to predict which inhibitors can bind to them. Herein we designed a
strategy to screen for small molecules by assesing whether they could directly bind/
interact with miR-10b/miR-21. As part of our results, we found a new mechanism of action
for the multi-tyrosine kinase inhibitor Linifanib (5-6A); it inhibits miR-10b in vitro in breast
cancer (BC) models. Furthermore, we confirmed that Linifanib (5-6A) interacts with the
precursor sequence of miR-10b through nuclear magnetic resonance (NMR). Overall, our
findings demonstrate an effective strategy to screen for small molecule inhibitors of
miRNAs (SMIRs), one that is applicable for any disease type in which miRNA
overexpression promotes pathology. More so, we provide a first-in-class lead compound
for further development in cancer therapeutics.
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CHAPTER I: Introduction

(Parts of this section were adapted with permission in part from: Monroig, P et al.,
MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities,
2013; Monroig, P et al., Small molecule compounds targeting miRNAs for
cancer therapy, 2015; and Berindan-Neagoe, I and Monroig P et al.,
MicroRNAome genome: A Treasure for Cancer Diagnosi s and Therapy
2014.)
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Breast Cancer

Breast cancer (BC) is the most common non-cutaneous cancer among American
women, accounting for approximately 1 in every 3 cancers diagnosed. There are more
than 1,300,000 cases and 450,000 deaths each year worldwide, making BC the second
leading cause of cancer death in females (exceeded only by lung cancer) [1-3]. The overall
worldwide burden of BC has doubled from the 1980’s until the present representing an
enormous threat to women’s health due to the number of patients being constantly
diagnosed [4]. The vast majority of the cases are seen in women over 40 years of age,
who have aggressive tumor types or that present at an advanced disease stage [5].

BC can be categorized under two main subgroups: sarcomas and carcinomas. The
former, are extremely rare types of histologically heterogeneous cancers that arise from
connective tissue components within the breast (such as myofibroblasts, lymph or blood
vessels). The latter, are tumors arising from the breast epithelium that consist on cells that
line the lobules as well as the ducts.

Carcinomas are the most common type of breast cancer, comprising malignancies
that are further categorized as either in situ or invasive. Carcinomas in situ are considered
a premalignant lesions composed of abnormal cells growing in their normal place, at a
point where they are not yet invading the breast tissue. They are clinically relevant
because they have been demonstrated to have the potential of progressing and
transforming into an invasive cancer. It is known that 15-53% of ductal carcinomas in situ
(DCIS) could become invasive over a period of 10 years if they remain untreated [6].
Similarly, lobular carcinoma in situ (LCIS) has been associated with an 8-11 fold increase
in the relative risk of breast cancer [7].
2

Invasive carcinomas, on the other hand represent the most aggressive
presentation of carcinoma, where cancer cells infiltrate the lobules and ducts and begin to
grow and spread into the breast connective tissue (Figure 1). Once invading the
surrounding tissue, the tumor can spread to distant body sites such as lymph nodes and
other organs. The majority of the invasive carcinomas are from ductal origin, accounting
for approximately 80% of the cases, followed by lobular carcinomas with 10-15% of them
[8]. The remaining cases are segregated as part of another group, in which they are
individually characterized by their pathological findings and are known to have different
prognosis as well as treatment implications. Some of these include tubular, colloid,
medullary, papillary and micropapillary.

Figure 1: Anatomical localization of invasive breast carcinomas
Lobular carcinoma in situ (LCIS) is an uncommon condition in which abnormal cells form
in the lobules or milk glands in the breast. Similarly, ductal carcinoma in situ (DCIS) is a
non-invasive cancer where abnormal cells surround the lining of the breast milk duct.
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Molecular and Histological Categorization of BC tumors

BC is a clinically heterogeneous disease which is categorized according to
immunohistochemistry/fluorescence in situ hybridization (IHC/FISH) profile, and is further
divided into different therapeutic groups based on the presence of estrogen receptor (ER),
progesterone receptor (PR) and HER2 (also known as ERBB2). More so, the analysis of
gene expression patterns identified by Perou and colleagues described four signatures:
luminal, HER2-enriched, basal-like, and normal breast-like subtype [9, 10]. Further along,
luminal tumors where separated into types A and B. Studies of these patterns have
demonstrated correlations between patient relapses, clinical outcomes, survival etc [11,
12]. These characterizations have led researchers to develop gene classifiers such as
PAM50 (Prediction Analysis of Microarray of 50 genes), which are able to define the major
intrinsic subtypes to which a tumor belongs to [13].

Recently, the addition of another molecular subtype has been described as
“claudin low” (CL), in tumors lacking tight junction proteins including claudin 3 and Ecadherin [14]. Additionally, the proliferation marker Ki-67 was associated with common
histopathological parameters, but was also another independent prognostic parameter
for disease free survival (DFS) and overall survival (OS) in BC patients [15]. Altogether
these descriptions and most recent findings underlie the importance of molecular and
histological characterizations in guiding therapeutic approaches as well as prognostic
predictions for breast cancer patients.

4

BC therapies

Over the past decade, we have witnessed a significant progress in early BC
detection and diagnosis. The favorable outcomes are in their majority attributed to the
enhancement of mammography screenings, which have reduced breast-cancer related
deaths by approximately 15-25% [16]. In addition, different therapeutic approaches have
been effectively used among patients, with surgery being one of the principal methods of
eliminating localized tumors. Alongside, multiple modalities including conventional
chemotherapy, molecular targeted therapy and endocrine therapy are being applied
individually or in combination with surgical approaches to target BC tumors [17].

Regarding the surgical management of breast cancer, several changes have
occurred over the past years. Breast conserving therapies, followed by radiation have
been validated for patients presenting with early tumor stages. These types of surgeries
are also used in cases of patients with locally advanced tumors, after preoperative
chemotherapy is given to decrease the tumor size. Sentinel node biopsy and axillary
lymph node dissection are considered “debatable approaches” with benefits and
unresolved issues on both. Finally, radical mastectomy remains a valid alternative in
selected cases [18].

In addition to surgical approaches, targeted therapies have been validated,
developed and used extensively over the past years in BC patients. The treatment of
choice for individual patients relies on the molecular markers characteristic of the tumors
themselves. Tumors with positive ER +/-PR, benefit from adjuvant endocrine therapy and
chemotherapy. In addition, the HER2 receptor status defines if a patient is subjected to
Trastuzumab (HER2 positive) or not. In patients with ER and PR negative tumors,
5

chemotherapy is the standard treatment (with Trastuzumab in HER2+ cases).
Nevertheless patients with TNBC tumors, the treatment guidelines are chemotherapy,
followed by surgery and lymph node dissection (www.nccn.org).

Even with aggressive, multidisciplinary approaches such as hormone therapy,
chemotherapy, HER2 targeted therapy and surgery; studies have demonstrated that there
are an unfortunate 30-50% of patients that relapse after their treatment (regardless of their
disease stage at the time of diagnosis) [19, 20]. For example, in patients with TNBC,
studies involving the administration of chemotherapy before surgery suggest that this
treatment is very effective only in the minority of women with this diagnosis (who have a
complete pathological response and thus an excellent outcome). In contrast, the outcome
for the majority of them is relatively poor, due to the presence of residual disease [21].
Additionally, some of the therapies being used have exhibited serious side effects and
toxicities [22]. Hence, there is an urgent unmet need to develop novel breakthrough of
drugs for BC therapy with higher safety profiles and therefore patient compliance and
therapeutic efficacy. With the aims of developing both local treatment of macroscopic
tumors and systemic therapies of microscopic disease, current researchers aim to prolong
the time of remission in patients and decrease the number of metastatic cases.

6

Figure 2: Summary of treatment guidelines for invasive breast carcinoma based on
receptor status (ww.nccn.org).

7

Non coding RNAs – A shift in the genetic paradigm

Years ago, researchers constantly emphasized that protein-coding genes were the
only relevant products of our genetic profile. This principle was propagated to very recent
times, until ncRNAs were discovered [23]. Today, a more complex view is emerging:
instead of focusing on genes, we have widened our research to non-coding genomic
regions that are actually transcribed from what was originally designated as the “junk pile”.
Furthermore, molecular biology has evolved and redefined dogmatic terms in the field,
nowadays considering the atomic unit for genetics the RNA transcript (not the gene per
se).

Important research projects focused on the human genome have been developed
over the years by scientists all over the world. Most of them have evolved around the
transcriptome encode by genes in humans. One of the most important studies was
ENCODE (The Encyclopedia of DNA Elements), which identified functional elements
demonstrating the fact that RNA can be dually processed yielding both, short and long
RNAs [24]. Alongside, it demonstrated that even though over 90% of the human genome
can be transcribed, only about 2% of it actually codifies for proteins [25]. Thus, a vast
number of transcripts, are non-protein coding RNAs (ncRNAs), that can function in many
ways, one of which is regulating transcription or translation of protein-coding genes [26,
27].
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MicroRNAs

For over ten years, non-coding RNAs (ncRNAs) have been demonstrated to be
involved in many regulatory mechanisms involving cellular physiological processes and
other biological ones.[28]. In the early 1990’s the understanding of lin-14, a gene in C.
elegans by Ambros and colleagues, guided the findings of a type of non-protein coding
RNA-transcript that negatively regulated translation through an antisense RNA-RNA
interaction. These elements were later referred to as microRNAs (miRNAs) [29]. However,
it was not only until the year 2000 that the characterization of a second RNA sequence
repressing protein expression elucidated the existence of a wider phenomenon
concerning an unknown genomic regulatory elements: microRNAs (miRNAs) [30].

MiRNAs are a type of non-coding RNAs of about 18-22 nucleotides (nt) in length
which have been validated to regulate genetic expression in a post transcriptional manner.
They are initially transcribed by RNA polymerase as independent genes, or as introns of
protein-coding genes [31]. Their widely known for targeting messenger RNAs (mRNAs)
causing critical changes that can directly inhibit translation, or that can cause mRNA
instability and therefore degradation. The majority of the protein coding genes
(approximately 60%), have been proven to be targeted by miRNAs through pairing
complementarity [32].

MiRNAs are transcribed from their particular coding gene, as a long primary
transcript which can fold upon itself further forming a doblue stranded hairpin (primiRNAs). An endonuclease, as well as a microprocessor complex (Drosha and DCGR8)
cleave the primary transcript forming a precursor sequence of approximately 70 nt in
length (pre-miRNAs). Proteins such as Exportin 5 and RAN-GTP promote the nuclear
9

translocation of the precursor sequences into the cytoplasm where another nuclease
called Dicer further cleaves it. Subsequently, the precursor sequences shortens to a
double stranded RNA sequence of 18-22 nt in length, which then separates into a guide
and passenger strand [33]. The guide strand promotes the association of a group of
proteins reffered to as an RNA-induced silencing complex (RISC) with the complementary
3’ unstranslated region of the mRNA (s) targeted by the specific miRNA. Even though their
main function is to target mRNAs, microRNAs have also been known to have many other
functions, such as regulating promoter regions, targeting cellular receptors, increasing the
stability of additional mRNAs, influencing cell signaling pathways etc [34].

10

Figure 3: MicroRNA biogenesis
MiRNA-coding genes are initially transcribed by an RNA polymerase II or III, creating a
primary transcript (pri-miRNAs), which can be hundreds or thousands of nt long. It is
further processed, into a 100 nt precursor transcript. The precursor sequence is then
exported to the cytoplasm, where it undergoes a series of processing events, prior to
achieving maturation. Once in the cytoplasm, mature single-stranded miRNAs are
integrated into a number of proteins that compose the RNA-induced silencing complex
(RISC), and thereafter they interact by sequence complementarity with the messenger
RNA (mRNA). In this way miRNAs inhibit translation or alternatively, they can increase
mRNA instability (consequently causing its degradation).
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MiRNA functions and role in cancer

The initial link between miRNA levels and cancer development was the miR-15
and miR-16 dysregulation in B cell CLL, as a result of chromosome 13q14 deletion [35].
Further studies have described the fact that many miRNA genes are located in fragile
genomic sites (regions more susceptible to mutations, rearrangements and loss of
heterozygosity), which are frequently found in tumorigenesis and cancer development
[36]. To date, miRNAs have been linked to angiogenesis, uncontrolled proliferation,
insensitivity to anti-growth signals, and every single one of the cancer hallmarks (Figure
4) [34]. They do so by tightly regulating tissue processes such as morphogenesis,
apoptosis, or others [37, 38]. Thus, in this way, the alteration of important messenger
RNAs (mRNAs) are involved in tumor initiation and progression, as these non-protein
coding genes behave as oncogenes or tumor suppressor genes [39].

Tumor suppressive miRNAs reduce the levels expression of oncogenes, and can
therefore delay carcinogenesis, or disrupt tumor maintenance. They are typically
downregulated in cancer. On the other hand, oncogenic miRNAs are typically
overexpressed or amplified in cancer, and they reduce the levels of important tumor
suppressor proteins. One example of each follows.

MiR-34a has been known as a classic example of a tumor suppressive miRNA. It
has been shown to be downregulated in several cancer types such as prostete. In prostate
cancer cells purified from xenograft and primary tumors, its expression was shown to
inhibit clonogenic expansion, and tumor regeneration as well as the process of metastasis
because of its targeting of CD44 (a cell- surface glycoprotein involved in cell–cell
interactions, cell adhesion and migration).
12

A representative example of an oncogenic miRNA is miR-224 in colorectal cancer
(CRC). MiR-224 expression increases consistently with tumor burden and enhances CRC
metastasis in vitro and in vivo. SMAD4 was identified as a translational regulator targeted
by this miRNA as demonstrated in clinical samples. Patients with high miR-224 levels had
shorter overall survival in multiple CRC cohorts and shorter metastasis-free survival [40].
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Figure 4: Examples of MicroRNAs Involved in the Cancer Hallmarks.
This figure is used with permission and originally published by Berindan-Neagoe, I., Monroig, P., Pasculli,
B., and Calin, G. in 2014 in A Cancer Journal for Clinicians
(http://onlinelibrary.wiley.com/doi/10.3322/caac.21244/epdf)

MiRNA-based therapeutic opportunities in cancer
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Two important strategies have guided the use of these molecules as novel
therapies. First, miRNA molecules have been modified to achieve a prolonged half-life
and efficiency in vivo (e.g. anti-miRNA and locked nucleic acid-modified oligonucleotides,
and antagomiRs). Second, the development of miRNA transgenic mice (such as the miR155, and miR17~92) and knockouts (such as miR-15, miR-16, miR-146 and miR-29) have
offered valuable information that has guided therapeutic opportunities for cancer patients
[41]. The strategies are based on the following principles: targeting oncogenic miRNAs to
decrease their levels expression; and restoring tumor suppressive miRNAs to rescue their
levels expression (Table 1).

i.

Inhibiting Oncogenic miRNAs

Cancer cells contain many genetic and epigenetic abnormalities, but despite their
complexity, their growth and survival can often be impaired by inactivating a single
oncogene. This phenomenon, called “oncogene addiction,” provides a rationale for
molecular targeted therapy [42]. Correlations between regulatory miRNAs and cancer
have revealed that this concept applies to miRNA dysregulation in patients. Thus,
regarding the first principle, therapies against oncogenic miRNA focus on decreasing
miRNA levels by inhibiting them through complementary base pairing.

Because of the diversity of mechanisms by which miRNA levels contribute to
tumor initiation and progression, several therapeutic models have been developed to
target these processes. Therapies to decrease the effect of a specific miRNA have been
proposed by using antisense oligonucleotides (ASOs) that inhibit targets by adhering to
the miRNA forming miRNAanti-miRNA binding complexes. Several types have been
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RNA therapeutic drug
Antisense oligonucleotides
(ASOs)

MicroRNA mimics

ASOs/AMOs, LNAs, and
antagomiRs

Small interfering RNAs
(siRNAs)

Definition
A single-stranded
chemically modified DNAlike molecule 17 to 22
nucleotides in length
designed to be
complementary to a
selected messenger RNA
(mRNA).
A microRNA (miRNA)
mimic is a small singlestrand 19 to 24 nucleotide
RNA with identical
sequence to the miRNA of
interest (to be reexpressed).
The ASOs/AMOs are
single-stranded,
chemically modified DNAlike molecules that are 17
to 22 nucleotides in length
and designed to be
complementary to a
selected miRNA and
specifically inhibits its
expression. The LNAs
anti-miRNAs represent
LNA-modified ASOs. The
antagomirs are singlestranded 23-nucleotide
RNA molecules
complementary to the
targeted miRNA that have
been modified to increase
the stability of the RNA
and protect it from
degradation.
A double-strand RNA
homologous to an mRNA
of a target gene.

Mechanism of Action
Specifically inhibits
expression of that gene
mainly through formation of
an mRNA-ASO duplex by
sequence complementarity,
leading to cleavage of the
mRNA of target gene.
Mimic the effects of an
endogenous miRNA with
consequent inhibition of
protein production by either
transcriptional inhibition or
translational block or both.
AMOs are ASOs against
miRNAs, and therefore
produce ASO-miRNA
duplex through sequence
complementarity, leading to
RNAse-H mediated
cleavage of the target
miRNA gene. The LNA
anti-miRNA have the same
mechanism as the
ASO/AMO. The
miRNA/antagomir-duplexes
induce degradation of the
miRNA and recycling of the
antagomir in a way still not
completely known.

The siRNAs are
incorporated into a
multiprotein RNA-induced
silencing complex, leaving
the antisense strand to
guide this complex to its
homologous mRNA target
for endonucleolytic
cleavage of mRNA.

Table 1: Principle Types of RNA-based therapeutic drugs
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described: antagomiRs, locked nucleic acids (LNAs) and ASOs with chemical alterations
to optimize efficacy (AMOs) (Table) [43-45]. With the use of antagomiRs, Fontana and
colleagues demonstrated that tumor growth was inhibited when injecting the antagomiR17-p in therapy resistant neuroblastoma cell lines [46]. In reference to the chemically
modified, Ma and colleagues used AMOs to intravenously inhibit miR-10b in a mammary
mouse tumor model, and observed that metastasis was inhibited [47]. Park and colleagues
tested another chemically modified antagomiR, chol-anti-miR-221. In their orthotopic
mouse model of hepatocellular carcinoma (HCC), they proved that chol-antimiR- 221
significantly reduced miR-221 levels in the liver, and that this, correlated with a reduction
in tumor cell proliferation, an increase in apoptosis markers and cell cycle arrest [48].
LNA’s, (another type of ASO) have also proven to be efficient, as a liver regeneration
mouse model tested by Sapra and colleagues demonstrated that using a locked nucleic
acid antisense oligonucleotide against survivin (an apoptosis inhibitor), reduced its mRNA
levels in 80%. In addition, researchers have recently engineered a single subunit termed
“multiple-target anti-miRNA antisense oligodeoxyribonucleotide” (MTg-AMO), through
which simultaneous silencing has been achieved [49]. MTg-AMO’s have been proven to
allow the restoration of dysregulated miRNA levels by targeting several key aspects of the
biology of cancer cells in tumor tissue at once. For example, Lu and colleagues
demonstrated that the MTg-AMO targeting miR-155 and miR-17-5p produced a greater
inhibitory effect on cancer cell growth, compared with the regular single-target AMOs [50].

Another therapeutic approach to decrease miRNA levels involves expressing
competitive inhibitors of their function. The typical example are “microRNA sponges” which
are vectors containing multiple artificial miRNA binding sites that are placed under the
control of strong promoters to produce large quantities of transcript [51]. These transcripts
express multiple tandem sites to a miRNA of interest [52]. MiRNA sponges were used in
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metastatic breast cancer mouse model, where in vivo experiments demonstrated that the
downregulation of an over-expressed breast cancer miRNA (miR-19) could be achieved,
along with metastasis inhibition [53].

ii.

Restoring tumor suppressive miRNAs

Although miRNAs are mostly known to be overexpressed in cancer tissue, they can
also be downregulated in tumors [54]. This fact recalls the second principle mentioned
above (regarding miRNA-therapeutics): restoring the levels of tumor suppressive miRNAs.
In the past, global repression of miRNA expression has been proven to increase
tumorigenesis in both in vitro and in vivo models [55]. For tumors with reduced expression
of miRNAs, restoring their basal levels is the key strategy, which can be achieved through
miRNA mimetics, which are synthetic small RNAs that contain the exact sequence of the
endogenous ones. To achieve the delivery of a stable molecule, miRNA’s are delivered
as perfectly complementary duplexes, similar in architecture to siRNAs [56].

The majority of the therapies that have tried to restore tumor suppressive miRNA
with mimetics have achieved their goal by administering them locally. However, nowadays
the challenge of developing a systemic delivery in a tissue/cell-type specific manner has
been proven to be achievable through different delivery systems. The lead candidate in
this field has been MRX34 from Mirna Therapeutics [57]. The liposome-encapsulated miR34 mimic for patients with unresectable primary liver cancer has evolved into a (currently
open) clinical trial. It is a phase I, open-label, multicenter dose-escalation study to
investigate the safety, pharmacokinetics and pharmacodynamics of the MRX34
(ClinicalTrials.gov Identifier: NCT01829971).
Oncogenic miRNAs miR-21 and miR-10b, and their role in BC
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Over the past years, the molecular mechanisms that underlie breast cancer
pathogenesis gave been extensively researched. However many challenges prevail when
managing patients. Some of these include: relapses, resistance to known treatments, and
metastasis. As regulators of tumor suppressor protein-coding genes, miRNAs where
thought to be attractive oncogenic agents to target in BC therapeutics. In the year 2005,
miRNA dysregulation was associated with BC for the first time [58]. Since then, many
studies have identified aberrantly expressed / clinically relevant miRNAs [59-62]. Two
examples of these are miR-10b and miR-21.

MiR-10b has been demonstrated to initiate tumor invasion and metastasis by positively
regulating cell migration and invasion in BC [63, 64]. It does so by indirectly causing the
activation of the pro-metastatic gene RHOC through suppression of HOXD10. HOXD10
is a transcriptional repressor involved in cellular migration and extracellular modelling
(such as RhoC, uPAR, α3-integrin and MT1-MMP) [65]. Furthermore, miR-10b has been
shown to be therapeutically relevant in mouse mammary tumor models, where its silencing
inhibited metastasis development [47]. Its clinical relevance has been seen in patient
samples, where miR-10b expression levels are lower in all of the breast carcinomas from
metastasis-free patients; but in contrast, the majority of metastasis-positive patients have
elevated miR-10b levels in their primary tumors [66]. This effect has been demonstrated
to be independent of the tumor subtype. Notably, overexpression of miR-10b in otherwise
non-metastatic breast cancer cells confers invasive and metastatic abilities on these cells
when they are growing (as proven in xenografts in vivo) [66]. Overall these facts thoroughly
exalt the importance of targeting miR-10b in BC therapeutics.
On the other hand, miR-21 has been found consistently upregulated in BC
carcinoma in situ compared to normal tissue [67]. In patients, levels of serum miR-21 has
been found to be significantly higher compared to controls, suggesting its usage as marker
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for early stage BC detection [68]. Its overexpression has been correlated with specific BC
bio-pathologic features such as advanced tumor stage, lymph node metastasis and also
with poor patient survival [69]. Several tumor suppressor proteins have been validated as
targeted by miR-21; some of these include TIMP3, ANKRD46, TPM1, PDCD4 and Maspin
[70-72]. Knockdown of miR-21 in BC cells has been demonstrated to inhibit migration in
vitro as well as growth in vitro and in vivo [71]. Therefore, the finidngs to this date also
suggest that miR-21 is another attractive miRNA to target in BC.

Interestingly, both miRNAs -10b and -21 have been identified as promoters of
metastatis progression (Figure 4) [72] .Thus, the discovery of a therapeutic agent that
could directly interact with miR-10b/miR-21 would open a new window of treatment
opportunities to explore against cancer; both, as a single agent or in combinatorial
therapies.
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Figure 5: MiRNAs -10b and -21 are involved in metastasis progression in BC
patients.
This figure was adapted and used with permission (and originally published by) Pencheva, N.
Tavazoie, S. F. Nature cell biology 2013
(http://www.nature.com/ncb/journal/v15/n6/full/ncb2769.html)
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Delivery Mechanisms

The main focus of miRNA-therapeutics is to be able to deliver the agents in vivo
(both locally and systemically). Local approaches such as direct site injection have several
evident advantages. Some of these are evasion of nuclease degradation, decrease uptake
by non-targeted tissues, and increase bioavailability at the tumor targeted site.
Nevertheless they are applicable to a limited number of tissues such as ocular and brain
[73]; and even in these tissues, not all targeted tumor cells are reached by the miRNAtherapeutic agents [74]. On the other hand, a systemic delivery consisting of a
bloodstream injection, theoretically should achieve a more efficient delivery to targeted
sites. Neverrtheless, this mechanisms have to overcome several barriers (in vivo) such as
nuclease degradation and non-specific targeting of tissues that are reached by blood
vessels nearby (eg. liver, jejunum, kidney) [74].

As an approach to surpass some of these obstacles, changes such as chemical
modifications, encapsulations and conjugations have aimed to protect miRNA-based
therapeutic agents so they can be stably conserved while in the bloodstream (where they
are required to maintain intact). In this way, they are able to traverse cellular membranes
and more importantly reach the cytosol, where they perform their main function [75]. Thus,
overall, the development of efficient carriers remains a challenge since synthesizing a
stable, biodegradable and biocompatible miRNA-therapeutic agent is important, but
ensuring an adequate cell penetration and molecular delivery is also crucial.

Current known carriers can be separated into 2 groups: viral and non-viral. Both
groups target tumor tissues and aim to evade immunological reactions / (cause toxicity).
Viral-based strategies have been used in the past with vectors such as lentivirus,
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adenoviruses and adenoassociated virus (AAVs), and through specific genetic
manipulation they have been able to target the tissues of choice [76, 77]. However, even
though preclinical in vivo models (using virus as vector-mediated delivery) have shown
promising results, they continue to present flaws that need to be addressed before
advancing into the clinic (such as undesired immunogenic responses) [75].

Non-viral strategies, such as liposomes, have been thoroughly used and have
proved to induce tumor suppression in vivo [78-80]. Their success has been accomplished
due to the evasion of the oligonucleotides from being degraded by nucleases, and due to
their ability to increase the circulating half-life when systemically delivered [73].
Nevertheless, some of these systems have had adverse effects in vivo, mostly related to
the positive charge of the lipid component (which also triggers undesired immune
responses) [73, 81].

A strategy that has begun to overcome these toxic effects has been the
development of neutrally charged liposomes, based on 1,2-dioleoyl-sn-glycero-3phosphatidylcholine (DOPC) [82]. In this way, nanoliposomes deliver microRNA-based
therapeutic agents into tumor cells much more efficiently in vivo. Several studies have
proven that this approach is effective. For example, in a mouse model for lung cancer,
Trang and colleagues systemically delivered the tumor suppressor miR-34a in a neutral
lipid emulsion and obtained a 60% reduction in tumor area compared to controls [83]. In
an additional model, mice with ovarian cancer tumors were treated with neutral-DOPC
liposomes thich incorporated siRNA to target the oncogene EphA2. Through their
experiments Landen and colleagues demonstarated that they could efficiently achieve a
reduction in tumor growth (compared to control) [84]. Interestingly, another approach
includes coating cationic bilayers with polyethylene glycol (PEG), demonstrated
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effectiveness and safety by decreasing immunogenic responses [85]. Finally the addition
of biodegradable synthetic or natural polymers could also represent an effective
alternative to facilitate sustained delivery in vivo, although once again, toxicity remains a
continuos challenge. Overall, the findings described above are still under development
and have not yet reached their primary endpoint completely. More so, the fact of having
to produce a delivery agent to administer therapy will continue to remain a burden, and
are consuming both: time and money.
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Small Molecule compounds targeting miRNAs for cancer therapy

Drug discovery and development are extremely long processes that take
approximately 10–15 years. In addition, drug production results in an incredible economic
burden that “boosts” their final overall cost, and patients end up having to pay exaggerated
prices for their treatments. Thus, time and cost are considered the main obstacles in
achieving new therapeutic alternatives for cancer treatment. Nonetheless, over the years,
the study of different types of proteins as well as other types of molecules, has led to the
discovery and identification of many inhibitors that are currently being used in the clinic.
More so, several therapeutic approaches using miRNAs have also begun to be developed.
However, even know some miRNA-based therapeutic strategies have been truly exciting,
there are challenges involved in the delivery of these non-small-molecule agents, and
even more, their pharmacodynamic and pharmacokinetic properties are not ideal for
clinical application [73, 81]. For this reason, there is still a need of developing new
alternative therapeutic approaches to inhibit oncomiRs, and decrease their activity.

Over the past years, significant attention has been focused on overexpressed
oncomiRs, and several studies have been published regarding the initiation and
development of a novel therapeutic approach for miRNA inhibition: the use of small
molecule inhibitors (Figure 6). Small molecules have been thoroughly used with clinical
applications for numerous diseases, but also specifically for cancer [86, 87]. The use of
chemical compounds that are already FDA approved to treat a specific disease (“X”),
would accelerate the process of completing toxicological studies and clinical trials in order
to apply it to another disease (“Y”). If a compound has already been through thorough preclinical testing and FDA-related studies (10 or more years), then using the exact
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compound for another disease would eliminate the need of going through the process
again (shortening both money expenses and time consuming processes).

On the other hand, small molecule compounds could facilitate the identification of
specific motifs from a lead compound. Then, by modifying the known compound rather
that designing a new one (“from scratch”), researchers could also decrease the time it
takes to synthesize and test a molecule de novo.

Figure 6: Small molecule compounds targeting microRNAs
This figure is used with permission and originally published by Monroig, P., Chen, L., Zhang, S., and Calin,
G. in 2015 in Advanced Drug Delivery Reviews
(http://www.sciencedirect.com/science/article/pii/S0169409X14002002)
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i.

A novel approach with new challenges
The interaction of small molecules and miRNAs was termed for the first time as

“SMIR” by Melo, Calin, and colleagues [88, 89], referring to small molecules inhibitors of
RNAs. The novel concept represented an attractive modality to eventually develop more
targeted cancer therapies. The idea of targeting RNAs, (in our case miRNAs specifically)
with small molecules seems very convenient in the sense that it is considered to be a way
of selecting a “fast-track pathway” in the drug developing race, reducing the time it takes
to develop, produce and approve drugs, not to mention the manufacturing (and overall)
cost of the process. If successful, targeting miRNAs with small molecules from which preclinical / clinical trials have previously been perfomed, could definitely result in an effective
drug, reaching the patient's bedside in an incredibly short period of time.

Although interesting, the idea behind targeting miRNAs with small molecules
involves embracing many risks and challenges. For example, compared to proteins, RNA
transcripts have never before been considered drug targets due to their electronegativity
and structural flexibility. More so, the absence of molecular structures of the majority of
the miRNAs, as well as the limited availability of miRNA-Dicer or RISC complex structures
makes their discovery increasingly difficult [90]. Nonetheless, recent findings suggest that
indeed miRNAs are good genetic elements to target [88]. The secondary structures of
immature miRNA transcripts, specifically in the pre-miRs, actually form stem loops and
bulges that facilitate their targeting by small molecule inhibitors. Thus, in this way, they
represent attractive “druggable” elements [91].

ii.

Developing a new concept
A few years ago, Deiters and colleagues described that there are 3 basic

processing stages which miRNAs require in order to perform their main function. More
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so, they envisioned that small molecules could indeed block miRNA maturation at all
3 of them: pre-transcriptionally, at the level of transcription, or post-transcriptionally
[92]. They determined that several ideas were possible; herein we briefly discuss them.

First of all, they perceived that pre-transcriptionally, small molecules could
decrease the levels of miRNA expression as well as their function [92]. By altering miRNA
promoter regions, small molecules where speculated to regulate miRNA expression in an
indirect way. Also, small molecules were thought to potentially inhibit deacetylation or
promote hypermethylation and thereby decrease the expression of miRNA-coding genes
[93, 94].

Secondly (but in a similar way), transcription factors were also thought as plausible
elements to be targeted by small molecules. By inhibiting their function, small molecules
could (in a way) decrease or inhibit completely the expression of genes coding for
miRNAs. For example, c-Myc has been demonstrated to activate the expression of 2
miRNAs from a cluster: miR-17-5p and miR-20a. Both of these are known to negatively
regulate the expression of E2F1, thereby promoting G1-to-S phase progression [95].
Thus, the idea behind this rationale was that a small molecule could target oncogenic
transcription factors such as E2F1, and in this way inhibit the expression of oncogenic
miRNAs (miR-17-5p and miR-20a) resulting in recovery of tumor suppressor proteins.

Thirdly, small molecules were also speculated to target the process of miRNA
biogenesis (post-transcriptionally), by inhibiting RNA-endonucleases (e.g. Drosha/Dicer),
or other important proteins [96-99]. These crucial elements, (required to produce mature
miRNA sequences), were thought to be potential targets to inhibit with small molecule
compounds in order to decrease the expression of oncogenic miRNAs.
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Overall, by comparing the different steps of miRNA regulation, research groups
speculated that targeting transcription was the most effective way of inhibiting miRNAs
[92]. However, the truth of the matter was that after different screenings were completed,
it was clear that targeting transcription factors was not a way of targeting miRNA
expression in a specific way. The rationale behind it is that transcription factors can
ubiquitously affect promoter regions of many genes simultaneously, including oncomiRs,
tumor suppressor miRs or genes coding for miRNAs that regulate cellular homeostasis.

Nowadays, after developing a deeper understanding of the field, the main goal of
the SMIR-based approach, is to discover compounds that can potently bind, and decrease
the levels of miRNAs in the most specific way possible [100]. The aim is for a small
molecule, to target a mature miRNA sequence by binding to it, or any of its upstream
precursors. If a small molecule inhibitor could be proven to bind to any of these sequences
directly, it could be used in any cancer type (or even disease) that overexpresses that
specific oncogenic miRNA. In order to achieve this, the initial step is determining which
miRNAs are important oncogenic targets. Following this, an efficient screening technique
needs to be developed and validated, in order to search for small molecule compounds
from chemical libraries.

iii.

Screening techniques to identify SMIRs
Screening chemical compound libraries is a drug-discovery approach broadly used

in research for many types of studies. The process usually involves “quick” methods to
assess the biological or biochemical activity of numerous compounds, in the shortest
amount of time with the highest precision possible. The identification of hit compounds
through screening techniques tipically provides a basis/starting point for future drug
design. Screening techniques have been used previously by several research groups in
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order to identify small molecule inhibitors of miRNAs [101-103]. The initial SMIR-screening
approaches can be done either in vitro or in silico; and both of these types of techniques
have been recently explored [103-109]. Herein we describe several assays used in vitro.
For a summary of in silico approaches to target SMIRs please refer to [100].

Assays detecting fluorescence
An example of an assay using fluorescence to detect changes in
miRNA levels are fluorescent beacons. These are oligonucleotide
hybridization probes that can report the presence or the absence of specific
nucleic acids (such as miRNAs) in solutions. They are hairpin shaped
molecules, composed of a quencher, as well as a fluorophore that can emit
fluorescence when interacting to its complementary target sequence. The
technique has been proven useful in past research studies [106, 107]. It is
performed by synthesizing a doubly-labeled precursor beacon containing a
5′ fluorescence emitter, and a 3′ quencher. Dicer-mediated hydrolysis of
the precursor results in a dissociation of the fluorescence emitter and
quencher, generating a Dicer-dependent increase in the fluorescence. If a
small molecule is not effective in inhibiting the miRNA, the miRNA itself
would bind its complementary sequence in the beacon and fluorescence
emission would be high. On the other hand, an effective SMIR would not
allow the miRNA to bind the beacon, therefore there would be less
fluorescence (Figure 7A).

Alternatively, another research group developed a DNA molecular
beacon that is independent of the precursor sequence and complementary
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to the mature miRNA produced after the Dicer cleavage (and in this way
Dicer cleavage is not expected to be altered in any way) [103]. .

Luciferase reporter constructs
Luciferase biosensors assays are an efficient / rapid screening
technique to determine the levels of miRNAs in vitro. These vectors are
usually assembled by introducing the complementary sequence of the
miRNA of interest. An additional vector with a control sequence,
downstream of a luciferase reporter gene is used alongside (to blank
artifact effect). The reporter constructs are then used as sensors to
determine the presence of specific mature miRNAs. The plasmids are
cloned and further sequenced, validated, and transfected into cells. The
system has been tested and proved efficient in detecting minor changes in
endogenous miRNA levels. The basis of the assay is as follows: in the
presence of a SMIR that efficiently targets the miRNA of interest, the
mature sequence is decreased, and the luciferase gene is expressed
constitutively. If the compounds tested do not inhibit the miRNA, then the
miRNA will bind to its target sequence and inhibit the expression of the
luciferase gene. Herein we briefly describe 2 examples.



pEZX-MT05 plasmid
The pEZX-MT05 vector from (GeneCopoeia) also offers the

opportunity

of

miRNA

target

identification.

Similarly,

miRNA

complementary 3′ UTR sequences are inserted downstream of the
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secreted Gaussia luciferase (GLuc) reporter gene in its respective vector
system, driven by SV40 promoter for expression in. Besides using GLuc as
the miRNA 3′ UTR target reporter, a secreted Alkaline Phosphatase
(SEAP) reporter driven by a CMV promoter, is also cloned and it serves as
the internal control. In addition to the GLuc/SEAP dualreporter vector
system, a firefly/Renilla Duo-Luciferase reporter vector (pEZX-MT01) has
also been validated and is currently available for SMIR screening [108].



psiCHECK-2 reporter plasmid
The psiCHECK2 vector (Promega) has been a useful tool to screen for

SMIRs in vitro. It is a reporter plasmid in which researchers clone a miRNA
target sequence downstream of a Renilla luciferase (Rluc) gene. The
presence / absence of a specific miRNA are directly proportional to
changes in the levels of expression of Rluc. This vector provides a very
significant advantage: it contains a Firefly luciferase (F-luc) gene which is
constitutively expressed. Thus, there is no need of co-transfecting a control
luc-gene (Figure 7B).

Stable cell lines
During the past years, many research groups have focused on
developing more efficient high-throughput screening techniques in order to
identify SMIRs. It has been proposed that using a stable cell line that
constitutively expresses a luciferase reporter, (rather than a transient
transfection), would be an approach more cost efficient and less timeconsuming. More so, it would eliminate variations associated with
transfection efficiency and other technical manipulations. This approach
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was tried by Connelly and colleagues; and in their study, they recorded the
steps needed to create a stable cell line with a constitutively expressed
vector [102]. In it they validated the Huh 7 cell line with a constitutive
expression of psiCHECK2 vector with the miR-122 target sequence [102].
This technique could be applied to any other cell line as well as any other
miRNA.
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(A)

(B)

Figure 7: Examples of high-throughput screening (in vitro) techniques for SMIRs
This figure is used with permission and originally published by Monroig, P., Chen, L., Zhang, S., and Calin,
G. in 2015 in Advanced Drug Delivery Reviews
(http://www.sciencedirect.com/science/article/pii/S0169409X14002002)
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Hypothesis and Aims of the Study
Even though miRNAs are small RNA molecules that do not codify for proteins, they
can regulate their expression in a significant manner. Due to their mechanism of action,
miRNAs have been demonstrated to be very important in contributing to the progress of
diseases such as cancer. This has compelled the progress of drug development
approaches such as the inhibition of oncogenic miRNA.

MiRNA expression in BC has proven to induce tumor initiation, progression and
metastasis. Death rates from BCs have decreased only slightly in the last decade, and
new therapeutic approaches are under scrutiny. To identify new therapeutic targets for BC
patients, we proposed to study oncogenic miRNAs that have been proven to target tumor
suppressor proteins in BC (miR-9, miR-10b, miR-21, miR-155, miR-181a, and miR-181b).
Among the miRNAs studied, two of them proved to be expressed at a significantly higher
level compared to the others: miR-10b and miR-21. Thus, for this project, we envisioned
the usage of small molecules to target and inhibit the function of these miRNAs.

Screening for small molecules inhibitors of miRNAs represents enormous challenges
Two of the most important ones are: (1) mature miRNAs are single stranded and
unstructured, and (2) there are few high resolution structures of immature miRNAs. Thus,
structure-based discovery is very difficult.

Encouragingly, we studied the in vitro strategies employed in a handful of trials
performed over the past few years (designed to identify small molecules inhibitors of
miRNAs through different approaches). Herein we proposed to generate a high-
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throughput screening system, to screen for small molecule compounds that can directly
interact and inhibit oncomir-10b / oncomiR-21.

Overall hypothesis:
Overexpressed oncogenic miRNAs can be inhibited by small molecules for BC
treatment. The targeted inhibition will have biological consequences in cancer cells.

We tested this hypothesis with the following specific aims:

Aim 1: To identify oncogenic miRNAs with clinical relevance in breast cancer, and
determine a strategy to screen for small molecule inhibitors that can target them.

Aim 2: To perform a high-throughput screening, and determine positive hit candidates
that can inhibit the identified oncogenic miRNAs.

Aim 3: To determine the efficiency, potency and specificity of the small molecule inhibitors
of the oncogenic miRNAs selected as targets; and to demonstrate the type of interaction
between the molecule and the miRNA.
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CHAPTER II: Methods

37

Integrative computational analysis and patient data selection. We performed a
literature review and selected a group of 6 miRNAs that were validated to have tumor
suppressor targets in breast cancer (through microRNA arrays, in vitro and in vivo models,
and/or patient cohort studies) [47, 53, 58, 63, 64, 66, 69, 71, 110-138]. Then, we obtained
clinical information and miRNA expression (miRSeq) from patients with invasive breast
carcinoma (BRCA), from “the Cancer Genome Atlas Project” (TCGA) available through
the associated files of the paper: Comprehensive molecular portraits of human breast
tumors, Nature, September 27, 2012 (https://tcgadata.nci.nih.gov/docs/ publications/) [3].
For these patients, we also downloaded their most recent clinical information from the
TCGA portal (http://tcgadata.nci.nih.gov/). We merged the clinical information from both
sources. All statistical analyses were performed in R (version 3.0.1). All tests were 2-sided
and considered statistically significant at the 0.05 level.

Kruskal-Wallis test was applied to assess the relationship among miRNA
expression levels in tumors and a box-and-whisker plot was used to visualize the miRSeq
data. Further along, the Shapiro-Wilk test was applied to determine whether data followed
a normal distribution. The t-test or analysis of variance (depending on the number of
groups considered) was applied to normally distributed data; otherwise the Mann-WhitneyWilcoxon test or again the Kruskal-Wallis test was applied to assess the relationship
between miRNA expression levels and clinical parameters. A box-and-whisker plot (Box
plot represents first (lower bound) and third (upper bound) quartiles, whiskers represent
1.5 times the interquartile range) was used to visualize the miRSeq data.

For each miRNA, we checked for a relation with the survival as follows. Patients
were grouped into percentiles according to the miRNA expression. The Log-rank test was
employed to determine the association between miRNA expression and overall survival
38

and the Kaplan-Meier method was used to generate survival curves. Cut-off points to
significantly split (log-rank test p-value <0.05) the samples into low/high miRNA groups
were recorded. The cut-off to optimally separate the patients in high/low (min p-value) was
chosen.

Cell Culture. Cell lines were obtained from the American Type Culture Collection
and grown as suggested by the supplier. Experiments were performed using The BC cells
MCF-7 cultured in DMEM plus 10% FBS, and MDA-MB-231 and MDA-MB-468 cultured in
RPMI. We also used 293FT cells which were grown in DMEM at 10% FBS. In addition we
used MiaPaCa-2, Hey-A8, HepG2, and DLD1 cells corresponding to pancreatic cancer,
ovarian cancer, hepatocellular carcinoma and colorectal cancer cells. The medias used
were the same ones suggested by ATCC, at 10%FBS. All cells where maintained at 37◦
C in a humidified atmosphere of 5% CO2.

miRNA correlation analysis. The Spearman's rank-order correlation test was
applied to measure the strength of the association between miR-10b and miR21. Statistical analysis and scatter plot graph were done using R (version 3.0.1)
(http:///www.r-project.org/) and the statistical significance were defined as a p-value less
0.05. We imposed also a cut-off of functional relevance on the Spearman correlation
coefficient in absolute value of 0.2 based on the method published previously [Integrated
genomic analyses of ovarian carcinoma, Nature 474 (2011), pp 609-615, (Table S7.1)]
[139].

Reporter Plasmid Construction. To develop a high-throughput screening system
for identifying microRNA inhibitors, we acquired the Psi-CHECK 2 luciferase reporter
vector (Promega). We then designed and acquired complementary oligonucleotides
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(Thermo Scientific) for hsa-miR-21 and hsa-miR-10b based on the mature miRNA
sequences for both (Appendix - Table 2). In the design of the exact microRNA target
sequence, we added several base pairs to have two different restriction sites recognizable
by the enzyme SgfI at one side, and PmeI on the other (both of the restriction sites were
present in the vector as well). In addition, the insert was designed with a restriction site for
SacI enzyme in order to have an additional site to digest the vector when monitoring
colonies for the presence/absence of the insert.

The designed oligonucleotides were annealed as follows. Complementary strands
were mixed at a 1:1 molar ratio in a microcentrifuge tube. The mixture was diluted to a
fnial concentration of 1pmol/µl with a buffer solution of 10mM Tris, 1mM EDTA, 50mM
NaCl (pH 8.0). The annealing reaction was prepared the same way for both miRNAs. In
brief, the reaction consisted of 1ul of 100µM oligo#1, 1uL of 100µM of oligo#2, 5µL of 0.5M
NaCl and 43µl of TE buffer. Both mixes were incubated at 95◦ C for 5 minutes, then the
heat was reduced gradually for 70 minutes, until reaching 4◦ C. Subsequently the reaction
was aliquoted and stored at -20◦ C.

The annealed oligonucleotides were digested along with the Psi-CHECK2 vector
with the enzymes were digested with SgfI and PmeI according to the manufacturer’s
protocols for the enzymes (New England Biolabs/NEB). In brief, 1µg of DNA was digested
with 1µl of each of the enzymes for 1 hour at 37◦ in a total reaction volume of 50µL.
Digested products where purified with a DNA purification kit (Qiagen). Vector and inserts
where ligated at the 3’-UTR (downstream) of the Renilla luciferase reporter gene in the
psiCHECK-2, using T4 ligase and buffer (NEB), at a ratio of 1:40 vector: insert (to ensure
insertion). Ligation was left for 2 hours at room temperature. Vector ligated without any
insert (oligonucleotide sequence) was used as control.
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Ligation reactions where transformed into One Shot Top 10 E. coli cells (Life
Technologies). Cells where initially thawed on ice and 2.5 µl of ligation reaction was added
to 25µl of competent cells and mixed gently by tapping. Mixes where then incubated on
ice for 30 minutes. Then reactions where “heat shocked” for 30 seconds at 42◦ C, followed
by a 2 minute incubation on ice. Subsequently, 250µl of SOC medium (at room
temperature) was added to each and incubated for 1 hour at 37◦ C shaking (200rpm). Each
reaction was then spread on pre-warmed plates with LB and ampicillin. Colonies were
then selected, and grown in LB broth overnight at 37◦ C shaking (200rpm). Vector
constructs were extracted from the bacteria using a mini-prep kit (Qiagen), according to
the manufacturer’s protocol. Insert sequences were further confirmed two ways. Firstly,
by enzymatic digestion (according to the manufacturer’s protocol - NEB), which was done
with SacI, for the restriction site we designed in the insert and BamHI, for a restriction site
contained in the vector (digestion with these two enzymes should theoretically give 2
products of approximately 1600bp and 4600bp). Secondly, the sequences were confirmed
by sequencing, with primer sequences described previously [140].

Sensitivity Assays for reporter vector constructs. A total of (2.0 x 104 MCF7cells/well) were plated the evening prior to transfection and treatment with a final volume
of media of 100µl. Cells where transfected with the psi-CHECK2 vector containing the
miR-10b target sequence, either alone or in combination with pre-miR-10b, or
antagomiR10b (acquired from Life Technologies). Concurrently, scramble sequences
were used as controls. All transfections were performed in triplicates for statistical
analysis. The exact protocol was used for miR-21 cloned vector as well. The final
concentration of the vector transfected was 25ng/100µl (250ng/mL), while for the
precursors and antagomiRs they were 50nm and 100nm respectively. Six hours after the
transfection, media was completely removed and replaced with new one. After 48 hours
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of incubation the media was removed, and cells were lysed and assayed with a Dual
Luciferase Assay (Promega) was performed using a Vi-Tech luminometer. The ratio of
Renilla to Firefly luciferase expression was calculated for each of the triplicates and the
data was analyzed.

Molecular Luciferase-Based Small Molecule Inhibitor Screening. An inhibitor
screening library of lyophilized and dissolved in DMSO was purchased (Selleckchem
Chemicals). Compounds from this company have been used in the past by different
research groups [141, 142]. MCF-7 cells were seeded 24 hours prior to transfection, in 96
well plates (2.0 x 104 cells/well).

All transfections were performed in triplicates for

statistical analysis. The cells were incubated at 37◦ C for 6 hours, followed by replacement
of the transfected media with fresh media containing the small molecule inhibitors to
screen at a concentration of 10 µM each. After 48 hours of incubation the media was
removed, and cells were lysed and Dual Luciferase Assay (Promega) was performed
using a Vi-Tech luminometer. The ratio of Renilla to Firefly luciferase expression was
calculated for each of the triplicates and the data was analyzed. Results of the complete
library after transfection with the luciferase construct and small molecule treatment were
merged together in 2 groups (according to the targeted miRNA -10b or 21. The top 5% of
compounds with the highest luciferase fold change were considered positive hits and
further studied.

RNA extraction. The media was removed from the plates containing the cells.
Cells were washed with PBS, and RNA was isolated using Trizol Reagent (Invitrogen).
RNA extraction was performed according to manufacturer’s instructions. RNA quantity
was assessed with NanoDrop ND-1000 (Thermo Fisher Scientific) and the integrity was
analyzed by gel electrophoresis.
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cDNA synthesis and quantitative real time PCR analysis. Positive hits from the
luciferase-based screening assay were selected to further confirm their potential as
SMIR’s. Their inhibition was tested in MCF-7 cells at the same concentration and time
point but through a different technique: RT-PCR. Cells were seeded in 6 well plates the
evening prior treatments at a confluency of 50-60%. They were then treated with the small
molecule compound hits, at a concentration of 10 µM and RNA was collected after 24 and
48 hours. MicroRNA expression was tested using TaqMan microRNA assay (Applied
Biosystems). The cDNA was synthesized using TaqMan Reverse Transcription Reagents
kit (Applied Biosystems) and employed for quantitative RT-PCR analysis together with
TaqMan probes and SsoFast Supermix (Bio-rad) according to the manufacturer’s protocol.
Primers and probes were purchased for hsa-miR-10b, hsa-miR-21, hsa-pri-miRNA-10b
and hsa-pri-21 and U6 snRNA (which was used as an internal control) (Appendix - Table
3). Experiments were performed in triplicates; treated samples were compared to the
DMSO solvent and normalized to the reference gene (snRNA U6) as an experimental
control. Relative expression levels were calculated using the 2-ΔCt method by Michael W.
Pfaffl [143].

To detect the levels of the precursor sequences, no commercial taqman probes
are available. Thus, cDNA was synthesized using the SuperScript III cDNA kit
(Invitrogen), and diluted cDNA was used for RT-PCR analysis using iQ SYBR Green
Supermix (Bio-Rad) with the appropriate primers (Table 4) according to the manufacturer’s
protocol. Relative expression levels were calculated using the 2-ΔCt method by Michael W.
Pfaffl [143].
Computational model of pre-mir-10b (third fragment) in complex with Linafinib.
The secondary structure of pre-mir-10b (third fragment) was predicted by CentroidFold
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[144, 145]. RNA tertiary structure was predicted by RNAComposer using the predicted
secondary structure as the constraints [146]. Molecular docking was performed using
rDock2006 [147, 148]. We explored the binding site using the geometrical center of
UG:AGU internal loop as sphere center, 15Å radius, and RbtCavityGridSF site searching
scoring function. A total of 200 separate runs were performed using rDock_solv scoring
function. We selected the binding mode that received the best rDock_solv score for
demonstration.

Lentivector-based MicroRNA Precursor Constructs. Primers for the precursor
sequences of each microRNA were designed (OligoPerfectTM Designer) including BamH1
and Ecor1/Not1 restriction sites (Appendix- Table 4). The amplicon was subsequently
confirmed by sequencing in the pCR2.1-Topo Vector (according to the manufacturer’s
protocol). We then digested the pCDH-CMV-MCS-EF1-copGFP vector (System
Biosciences), along with the vector containing our insert. Subsequently, we ligated and
purified the construct already containing the precursor sequences of our interest with a kit
for DNA purification (QIAGEN) according to the manufacturer’s protocol.

For the lentiviral production, 293FT cells were grown in DMEM supplemented with
10% FBS and “splitted” when they were 80% confluent. Cells were transfected in 10cm
dishes when 60% confluent with 8.0µg of transfer vector (pMirna – System Biosciences),
5.2µg of the packaging vector (CDH-CMV MCS-EF1-copGFP) and 2.8µg of the envelope
vector (pMD.G – System biosciences). After 48 hours of incubation the supernatant
containing the virus was collected and filtered (0.45 micrometers). MCF7 cells were then
taken to infect with the virus supernatant, containing either the empty vector, or the vector
containing sequences for pre-miR10b or -21. When 60% confluent, 2mL of viral
supernatant was added to the cells, along with Polybrene/Sequabrene antibiotic, at a final
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concentration of 8µg/mL. The plate was then centrifuged 1500-1800g for 90 minutes, and
incubated at 37◦ C for 30 minutes. Finally the media was removed and replaced with fresh
one. Transfection efficiency was monitored through GFP, as well as RT-PCR.

Dose-Dependent Cell-based assays. The luciferase-reporter vector construct was
used to test the half maximal effective concentration (EC50) at which each small molecule
inhibitor induced a response halfway between the baseline and maximum after a specified
exposure time. Cells were plated at a 50-60% confluence the evening prior transfection.
Transfection was performed as initially done for the screening, and effectiveness of small
molecule inhibitors was tested at three separate time-points 24 and 48 hours. A total of 5
different concentrations were tested in serial dilutions and the EC-50 was determined for
each compound using MCF7 cells.

Cell Viability. Cell viability and IC50 were determined by the 3-(4,5-dimethyl-2thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT assay). Briefly, 2.0 x 104 MCF7cells/well were plated the evening prior to treatment in 96 well microculture plates. After
cells were adherent, 5 different doses of the drugs were added to the supernatant. After
24 and 48 hours, the MTT reagent (Sigma) was added to each well and incubated for 3
hours at 37◦ C. The optical density (OD) was read at 570nm on a microplate
spectrophotometer and growth values (%) were calculated as (OD treated cells / OD
untreated cells) x 100. The experiments were performed in quadruplicates after 24 and 48
hours.

In vitro migration and invasion assay. For migration, 8 micron translucent inserts
for 24 well plates were covered with gelatin (100µL) were put to gently shake/rotate for 2
hours. Excess solution was discarded, and plates were left to dry under sterile conditions
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for 1 hour. Following this, 50,000 cells were seeded onto the top of gelatin-coated insert
and 500 μl of media with 10% FBS was added to the bottom of each well. Cells were left
to migrate 24 hours. The cells that migrated to the bottom of the well were fixed, stained
(HEMA 3 stain set – according to manufacturer’s instructions), and counted using a
microscope. For each well, 5 different fields were counted and the average number of
cells was determined. The experiments were performed in triplicates. The same protocol
was used for invasion assay with a top coat containing collagen and laminin. Results were
normalized for proliferation

Proliferation assay: Cell proliferation was determined using a colorimetric assay
were the highly water-soluble tetrazolium salt WST-8 (Dojindo Molecular Technologies) is
reduced by dehydrogenase activities in cells to give a yellow-color formazan dye, which
is soluble in the tissue culture media. The amount of the formazan dye, (generated by the
activities of dehydrogenases in cells, and directly proportional to the number of living cells)
was measured after 3 hours of incubation. The OD was read at 450 nm on a microplate
spectrophotometer and growth values (%) were calculated as (ODtreated cells
/ODuntreated cells) x 100. The experiments were performed in triplicate.

Statistical analysis The qRT-PCR, luciferase dosage dependent analysis,
migration and invasion assays were performed in triplicates. A (two-sided) t-test was
applied to compare the mean between control and treated samples. Analyses were carried
out in GraphPad (Prism 6). The statistical significance was defined as a p-value less 0.05.
MTT assay: data and analysis The MTT experiments were performed in quadruplicates.
A (two-sided) t-test was applied to compare the mean between solvent control and treated
samples. Analyses were carried out in GraphPad (Prism 6). The statistical significance
was defined as a p-value less 0.05.
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Nuclear Magnetic Resonance. The human microRNA sequences were obtained from
miRBase database (http://www.mirbase.org/). RNA molecules were prepared by in vitro
transcription using T7 RNA polymerase (approximately 2 ml reaction) using 15N isotope
labeled 5'-NTPs (nucleoside triphosphates) and purified over PAGE gels using
established procedures [149, 150]. Resonance assignments for the RNA hairpins
containing the target motifs were be obtained using standard homonuclear and
heteronuclear multidimensional NMR techniques (e.g. HCCH-TOCSY, HNN-COSY, and
13

C- or 15N-edited 3D NOESY-HMQC) [151]. Inter-proton distances were derived from 1H-

H NOESY and 13C/15N-edited 3D NOE-based spectra. Residual dipolar couplings (RDC’s)

1

were generated by Pf1 phage-induced weak alignment of the RNA molecules and
incorporated into the structure determination [152-155]. Assignment of constraint values
and the structure calculation protocols were similar to those in the following manuscripts
[152, 155-157].

Spectrums of the RNA and the DMSO (solvent) were used as controls. Peaks in the
samples with the RNA and small molecules were compared to the control spectrums to
predict miRNA-compound interactions. To confirm peak changes in any positive 2D NMR,
we designed RNA Oligonucleotide sequences (Dharmacon) to create shorter segments
of the primary transcript of miR-10b of approximately 50 base pairs (with some bases
overlapping each other between sequences). We then read a 1D NMR spectrum to
determine in a more precise way in which segment of the primary the molecule was
binding to.
Western Blot. Proteins were lysed with Lysis buffer (Cell Signalling Technology),
diluted from 100X up to 1x, as well as phosphatase and protease inhibitors (also diluted
from 100X to 1X). Cells were washed with PBS to remove residual medium. A total of 50
– 100µl of cold 1x LB was added, and cells were mixed by pipetting. Subsequently cells
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were incubated on ice for minimum 10 minutes with vortex every other minute during the
time. Then lysate was centrifuged at maximum speed for 10 minutes at 4C. Supernatant
where transferred to a new tube and stored at -80C until used.

For

protein

quantification

the

equipment

used

was:

Smartspec

Plus

Spactrophotometer (BioRad) and the BioRad Dye Reagent was used to dilute the proteins
(1:1000). Criterion pre-casted gels (4-20% Tris-HCl 1.0mm) were used (BioRad), at a
constant mAmp of 35 and a voltage of 160. “Trans-blot Turbo Transfer packs” were used
to transfer the proteins to 0.2 µM nitrocellulose membranse, for a ten minutes (dry
transfer). Membranes were blocked with 5% milk for one hour. Primary antibodies were
left overnight, and secondary antibodies were left for 1-2 hours.

Ingeuity Pathway Analysis (IPA). A detailed description of IPA can be found at
http://www.Ingenuity.com. Genes of interest were entered into Path Designer using “My
Pathway” function. Path Explorer tool was used to identify the shortest pathways among
the genes using both Ingenuity pathway analysis knowledge base and external databases.
Grow tool under “Build Tab” was also used to simultaneously explore direct or indirect
relationships for either down-stream or up-stream molecules of the miRNA genes of
interest.

Identification of miRNA/mRNA target interactions /functional profiling. A large number
of target prediction programs and databases on experimentally validated information have
been developed for miRNAs. For miR-10b and miR-21, we retrieved data on miRNAmRNA interaction predictions and miRNA-mRNA validated interactions from miRWalk
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/).
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miRWalk is a comprehensive

database on miRNAs, which hosts predicted miRNA-mRNA interactions (given by 8
algorithms), as well as validated miRNA-mRNA binding sites. We also downloaded
information

on

validated

miRNA

-

target

interactions

from

miRTarBase

(http://mirtarbase.mbc.nctu.edu.tw/). The data base miRTarBase accumulates miRNAtarget interactions (MTIs), which are collected by manually surveying literature (the
collected MTIs are validated experimentally by reporter assay, western blot, or microarray
experiments with overexpression or knockdown of miRNAs). For further analyses we
chose mRNA targets predicted by at least 4 programs and/or validated by multiple assays.
We used then KEGG Database Resource (http://www.genome.jp/kegg/) and PANTHER
(http://pantherdb.org/) for a functional profiling of miRNA targets.
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CHAPTER III: Results
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Evaluation of the clinical significance of validated oncomiRs in BC

Initially we carried out a literature review of recently validated oncomiRs in BC. The
majority of the studies used where published within the last 5 years. We then selected a
total of 6 microRNAs which were found to be highlighted as oncogenic in different BC
studies in vitro / in vivo, and also in patient samples. These were: miR-9, miR-10b, miR21, miR-155, miR-181a and miR-181b. Following the selection of miRNAs, we carried out
an integrative computational analysis to identify their clinical relevance within tumor
samples from invasive BC patients. Using The Cancer Genome Atlas (TCGA) patient
datasets of invasive breast carcinoma tumors, we found that miR-10b and miR-21 were
overexpressed at statistically significant level when compared to all the others (both with
a P<0.0001) (Figure 8). Thus, we selected these 2 oncomiRs for the purposes of our
studies.

mirSeq log2(x)

Invasive Breast Cancer Tumor Samples

miR-21
n=590

miR-10b
n=590

miR-181a
n=590

miR-181b
n=590

miR-9
n=590

miR-155
n=590

Figure 8: Oncomirs -21 and -10b are highly expressed in invasive breast carcinoma
tumors.
Using TCGA patient data sets of all BC tumor types, a comparison between the levels of
expression of miRs: -9, -10b, -21, -155, -181a, -181b, yield that miR-21 and miR-10b are
expressed at a statistically significant higher level.
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The expression of oncomiRs -10b and -21 are not correlated in BC patient
samples.

Within the TCGA patient dataset, we investigated if the levels of expression of both
of these miRNAs were correlated. Initially we tested the complete datasate of invasive
breast carcinoma tumors (n=590). Within the pooled set of samples, we found a correlation
coefficient of -0.25; which, although negative, suggested statistical but not biological
significance.

We then separated the patient samples into 2 groups. As part of our first group,
we selected patients with tumors types between stages I and II. In the second group we
pulled together the patients with tumor between stages III and IV. Within these groups we
did not find any correlation in the expression of miR-21 and miR-10b (Figure 9). We also
divided patient samples by specific receptor status (ER, PR, TNBC), and found no
significant correlation between the expression levels of both miRNAs (data not shown).
Thus, we concluded their expression is not correlated in BC.
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Figure 9: The expression of oncomirs -21 and -10b is not correlated in BC patients
Using TCGA patient data sets of all BC tumor types, we investigated if the expression of
miRNAs -21 and -10b was correlated. Comparison between all the samples resulted in a
small negative correlation (coefficient of -0.25). Although statistically significant these
results did not suggest a significant biological correlation. More so, dividing the patients
by specific tumor stages did not yield any correlation between the expression of miR-10b
and -21.
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Individual assessment of miR-10b/-21 levels of expression within specific BC
tumor subtypes

In order to better understand the significance of the miR-10b and miR-21
overexpression in invasive breast carcinoma samples from patients (TCGA database), se
grouped them according to their estrogen, progesterone and HER2 receptor status. We
found a significant increase in the levels of expression of miR-10b, in ER+ subtypes
compared to their negative counterparts (Figure 10A). Similarly, PR+ patient tumor
samples had higher miR-10b levels compared to negative tumor types (Figure 10B). We
further confirmed this tendency by studying samples from patients with TNBC tumors, and
found that the levels of miR-10b were significantly lower in the group of patients with TNBC
tumor types (compared to non-TNBC) (Figure 10C). We thus confirmed for the first time
to our knowledge, that high levels of miR-10b are characteristic of ER+PR+ subtypes of
breast cancer tumors.

Within the same group of tumor samples (grouped by the expression of ER, PR
and HER2), we analyzed the expression levels of miR-21. Interestingly there was no
difference in the levels of miR-21 between ER/PR +/- tumor samples (Figure 11A and
11B), nor so in TNBC or non-TNBC (Figure 11C). We thus confirmed, not only that miR21 is overexpressed in invasive breast carcinoma samples, but that its overexpression
seems to be independent of the molecular classification of the tumor type (ER/PR/HER2).
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(A)

(B)

(C)

Figure 10: Levels of expression of miRNA -10b within subgroups of BC patients
classified by estrogen, progesterone and HER2 receptor status.
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(A)

(B)

(C)

Figure 11: Levels of expression of miRNA -21 within subgroups of BC patients
classified by estrogen, progesterone and HER2 receptor status.
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Expression of miR-10b and miR -21 influence overall survival of ER+ BC patients

We determined to identify the influence of miR-10b and miR-21 overexpression in the
overall survival (OS) of BC patients. Once again, using TCGA patient datasets, we
analyzed the clinical correlation of the expression levels of miR-10b and miR-21 in
different BC tumor subtypes. Our results demonstrated that miR-10b is associated with
decreased OS, specifically in early tumor stages (I-II) of patients with ER+ tumor types
(Figure 12A). Similarly, miR-21 overexpression correlated with OS in ER+ tumors;
however, it was statistically significant only at later tumor stages (III-IV) (Figure 12B).
Thus, we confirmed that both oncomirs are clinically relevant, but also, we identified a
specific group of BC patients that could benefit from a miRNA-targeted therapy.

(A)

(B)

Figure 12: High levels of expression of miRNAs -10b and -21 correlate with
decreased OS in BC patients.
(A) High levels of expression of miR-10b are associated with decreased OS, of patients
within early stages (I-II) of ER+ tumors. (B) Similarly, high levels of expression of miR-21
also correlate with decreased OS in patients within tumor stages III-IV.
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High-throughput screening of small molecule inhibitors targeting miR-10b/ miR-21

With the aims of discovering novel therapeutic approaches for BC patients, we
designed a step-wise approach to screen, detect and validate SMIRs targeting miR-10b
or miR-21 through different assays (Figure 13).

Small Molecule
Chemical Library of
Compounds
miR-10b

miR-21
(481)

- HTS: Dual Luciferase biosensor assay

(21)

(19)

- Confirmatory RT-qPCR: mature miRNA sequences
- Validation: second cell line model

(3)
(12)
- Specificity: Determination of levels of alternative oncomirs
- Efficiency and toxicity: Determination of IC50’s and EC50’s

(3)
- RT-qPCR: pri-miR and pre-miR
- Nuclear magnetic resonance (NMR)
Functional Assays:
Migration/Invasion
miRNA targeted-protein recovery:
Western Blot

(1)

Figure 13: Screening Design
Summary of the steps used to determine if small molecule inhibitors targeted miR10b/-21.
The number of compounds remaining in the study after each step is shown.
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Initially

we

constructed

a

reporter

vector

designed

with

complementary

oligonucleotides for miR-10b, and another one for miR-21. We cloned these sequences
on a psi-CHECK2 vector, downstream of a Renilla luciferase reporter gene (Figure 14A).
We then tested the effectiveness of the cloning, by sequencing and also by verifying the
presence of the insert in both of the vectors constructed. For the latter, we digested the
vectors with SacI and BamH1 enzymes, for which restriction sites were present in the
insert and vector (respectively). In the presence of the insert, the construct was cleaved
at 2 sites (yielding 2 separate bands seen on agarose gels). On the other hand, if the
vectors where empty (ligated upon themselves) only 1 band could be seen in the agarose
gels (Figure 14B and 14C).

Further along we tested the sensitivity of the reporter in detecting changes in the levels
of expression of the miRNA for which they had the complementary target sequence. To
do this, we transfected them into MCF-7 cells and alongside, we also added antagomiR10b/-21 or pre-miR10b/-21, to verify that the assay was sensitive in detecting the changes
in their levels. In the presence of antagomiRs, luciferase expression increased
significantly. On the other hand, in the presence of precursors, it decreased (when tested
48 hours after transfection) (Figure 15A and 15B). Given the fact that the assay proved
sensitive, we used it as the initial step of our screening (refer to Figure 13).

Given the fact that miR-10a varies only by 1 in comparison with miR-10b, we also
performed the sensitivity assay with antagomiRs and precursors for miR-10a for the psiCHECK2 vector containing the miR-10b target sequence. We found no statistically
significant changes in luciferase expression when altering levels of miR-10a (AppendixFigure 38). Our results once again suggested sensitivity and specificity, only towards
changies in miR-10b levels.
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We screened a library of 450 small molecule inhibitors. A total of 6/96-well plates with
scattered solvent controls were tested. The results of all six plates were merged, and are
reported (Figure 15C). For results representing individual plates per compound, refer to
the Appendix- Figures 39, 40 and 41. Compounds representing the top 5 % of compounds
with the highest luciferase fold change expression were considered miR-10b small
molecule inhibitor hits, and submitted to further testing.
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Figure 14: Cloning of Psi-CHECK2 Luciferase vector constructs
(A) Psi-CHECK-2 vector was used to clone the miR-10b / miR-21 target sequences
downstream of a Renilla luciferase (Rluc) gene. After the transformation, vectors were
extracted from E. coli colonies, and digested with SacI and BamHI enzymes to confirm the
presence or absence of the insert. (B) Representative colonies from psi-CHECK2+
miR10b target sequence. (C) Representative colonies from psi-CHECK2+ miR21 target
sequence.
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Figure 15: Luciferase-based microRNA biosensor assay detects changes in the
expression levels of miR-10b and miR-21.
(A and B) To test the sensitivity of the reporter vector construct, we transfected the vectors
into MCF-7 cells, along with antagomirs/precursor sequences for miR-10b / miR-21.
Luciferase expression increased significantly in the presence of antagomiRs, and
decrease concurrently with the addition of precursor sequences. (C) Screening results of
the acquired library revealed potential SMIR-10b/-21 candidates. Approximately 20
compounds were selected from the top 5% with the highest luciferase expression. These
were determined to be positive hits, and thus were chosen to perform confirmatory assays.
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Validation of SMIR-10b and SMIR-21 candidates

As a second step in our screening, we tested the positive hits from the luciferasebased reporter assay with a technique that increased sensitivity: real time-quantitative
polymerase chain reaction (RT-qPCR). MiR-10b / -21 inhibitions were evaluated by RTqPCR in MCF-7 cells at the same time point and under the same conditions at which the
luciferase assay was performed (48 hours). Compounds confirmed as hits in the RT-PCR
were considered “true positives”. Non-confirmed hits were considered “false-positives”,
and therefore eliminated from our screening. In all, a total of 13 compounds were
confirmed to decrease the levels of miR-10b, and 2 where confirmed to decrease miR-21
(Figures 16A and 16B respectively).

To further validate specific hits, we decided to verify whether the inhibition could also
be achieved in one additional BC cell line model (MDA-MB-231 or MDA-MB-468, both
triple negative). For this, we selected each of the validated hits, and repeated the exact
same treatment conditions in one additional cell line, at two time points (24 and 48 hours).
We observed that all the SMIR-10b and SMIR-21 validated hits inhibited miR-10b and
miR-21 respectively in at least 1 additional cell line model under the same conditions
(Figure 17 – Panels A, B and C). These results confirmed our previous findings in MCF-7
cells, and demonstrated that the inhibition was not cell line-specific.
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qRT-PCR was used as a confirmatory assay to increase the sensitivity of our screening
results. We evaluated miR-10b/miR-21 inhibition in MCF-7 cells at the same time point at
which the luciferase assay was performed (48 hours). Compounds confirmed to be
positive hits in the RT-PCR were considered “true positives” (shown as filled bar graphs).
Non-confirmed hits were considered “false-positives” (shown as empty bar graphs).
Several hit compounds belonged to the same family of inhibitors (shown as filled bar
graphs with different patterns - per family type).
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Figure 16: Validation of SMIR candidates using qRT-QPCR
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(NOTE: Panel B of this figure, as well as the figure legend appears on the
following page.)
65

o

u

S

rs

O

rs
o

u

rs

O
S

u

o

H

H

2

8

8

4

o

o

H

H

4

4

0 .5

0 .0

4

2

u

rs

M

M

u

rs

D

D

S

O

2

0 .0

*
*
*

M

***

*

D

***

0 .5

1 .0

Fold Change
in miR-10b levels

1 .0

Fold Change
in miR-10b levels

Fold Change
in miR-10b levels

1 .0

(B)

1 .0

*

0 .5

0 .0

1 .0

*

***

0 .5

0 .0

D

M

S

O
2

4

H

o

u

rs
4

8

H

o

u

MDA-MB-231
6-1F
Fold Change
in miR-10b levels

1 .5

MDA-MB-231
6-11E
Fold Change
in miR-10b levels

Fold Change
in miR-10b levels

MDA-MB-231
6-7C

1 .0

0 .5

****
****

0 .0

rs

D

M

S

O
2

4

h

o

u

rs
4

8

h

o

u

rs
D

M

S

O
2

4

h

o

u

rs
4

8

h

o

u

rs

(C)

1 .0

****

****

0 .5

0 .0

MDA-MB-231
4-6A
Fold Change
in miR-10b levels

Fold Change
in miR-10b levels

MDA-MB-231
3-3G

****

1 .0

****
0 .5

0 .0

D

M

S

O
2

4

H

o

u

rs
4

8

H

o

u

rs

D

M

S

O
2

4

H

o

u

rs
4

8

H

o

u

rs

Figure 17: True positive SMIR compounds validated in TNBC cell lines (MDA-MB231 or MDA-MB-468). Panels A and B - All of the “true positive” SMIR-10b hits were
treated at two time-points (24 and 48 hours), and all of them decreased miR-10b levels.
The results were statistically significant when treated under the same conditions used in
the initial screening assay. Panel C – The 2 “true positive” SMIR-21 hits were treated at
two time-points (24 and 48 hours). They both decreased miR-10b levels, and the results
were statistically significant after 24 and 48 hours of treatment.
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Determining the specificity of oncomiR inhibition by SMIR candidates

As the following step of our screening, we determined to identify possible off-target
effect of the SMIRs, such as inhibiting other oncomiRs (not-10b / -21). For this, we used
RNA from MCF-7 cells that had been previously treated with the SMIR hits (for both
miRNAs). We then verified the levels of expression additional oncogenic miRNAs, to
determine the specificity of the molecules (Figure 18A-F and Figure 19A-B respectively).
We selected 4 oncogenic miRNAs from the group of 6 which we had initially found to have
validated tumor suppressor targets in our literature review (-9, -155, -181a, -181b) [53,
110, 111, 158]. For compounds of the same family (inhibitors of the same protein), we
only tested 1-2 compounds, and the rationale behind this decision was that if compounds
of the same family of inhibitors are decreasing the levels of miR-10b or -21, it is highly
probable that the mechanism of action (mechanism of miRNA inhibition) is an indirect one
(and not a direct one, which is the focus of our study).

After verifying the levels other oncogenic miRNAs we divided the compounds into one
of two groups: a “specific hits” group (defined as compounds that only altered the levels
miR-10b, and not additional miRNAs), or “non-specific” group (defined as groups that
decreased the levels additional miRNAs). The RT-PCR analysis of 4 oncomirs allowed the
definition of a spectrum of specificity for each of the candidates. For example, compound
6-11E from the family of HSP90 inhibitors was considered part of the group of “non-specific
hits” (Figure 18E). On the other hand, compounds: 1-6D, 5-6A and 6-7C were considered
“specific hits”, because treatment with them didn’t affect the levels of additional miRNAs
tested (Figures 18A, 18B and 18C).
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Figure 18: Levels of oncogenic miRNAs (-9, -155, -181a, -181b) in BC cells treated
with SMIR-10b compound hits.
For SMIR-10b hit compounds, we tested the levels of expression of alternative oncomiRs
after treatment with the SMIR-10b hits (A) 1-6D, (B) 5-6A, (C) 6-7C, (D) 3-3H and (E) 611E, (F) 6-1F.
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Figure 19: Levels of oncogenic miRNAs (-9, -155, -181a, -181b) in BC cells treated
with SMIR-21 compound hits.
For SMIR-21 hit compounds, we tested the levels of expression of alternative oncomiRs
after treatment with the SMIR-21 hits (A) 3-3G and (B) 4-6A.
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Non-specific hits reveal a role of Heat Shock Protein 90 in regulating miR-10b levels

A total of 8 molecules, (out of the 13 confirmed miR-10b positive hits) belonged to the
same type of family: inhibitors of heat-shock protein 90. Out of the 8 compounds, the RNA
of 3 was tested to determine if the treatment also inhibited other oncogenic miRNAs in two
different cell line models (Figures 18E, 18F). Since they also inhibited other miRNAs we
grouped them in the “non-specifics” group of hits. Nevertheless, we observed that these,
the inhibition of mIR-10b seemed to be strong, and the results were consistent among
them. Thus, we selected the 2 most potent representatives from the family, 6-1F and 611E to pursue further studies.

For third time, we tested for miR-10b inhibition in MCF-7 cells after 24 and 48 hours of
treatment (Figure 20 – left panel). More so, compound 6-1F decreased the levels of miR10b in MDA-MB231 after both: 24 and 48 hours of treatment, by approximately 65% and
80% respectively (Figure 20 – bottom panel / right). Similar results were obtained with
compound 6-11E decreased miR-10b levels after 24 and 48 hours of treatment by 25%
and 50% respectively in an additional cell line tested (MDA-MB-231) (Figure 20 – bottom
panel / left). Since the inhibition proved to be strong, we continued studying alongside, the
role of HSP90 in regulating miR-10b in other cancer types.

The 8 HSP90 inhibitors that formed part of our library had different chemical structures
(Appendix Table 6). Furthermore, they were previously used in an array of clinical trials
for different diseases such as cardiovascular disease, asthma, depression and cancer.
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However, their most significant common feature is the protein they target: HSP90. We
therefore hypothesized that indeed it was the inhibition of the HSP90 protein itself what
was causing the down-regulation of miR-10b (rather than a direct interaction). To further
explore the mechanism, we tested for the levels of the primary and precursor transcripts
of miR-10b, to determine if the inhibition was achieved by targeting miR-10b biogenesis/
maturation. We found both the primary and precursor transcripts were also significantly
decreased in MDA-MB-231 cells (Figure 21).

We also investigated the possibility of validating our results in other cancer models in
vitro. We thus tested 2 additional cancer types that have been recently linked to miR-10b,
ovarian and pancreatic cancer [159-161]. We treated the ovarian and pancreatic cell lines
HeyA8 and MiaPaca2 with two representative inhibitors of the HSP90 family. Our results
demonstrated that miR-10b was inhibited in a time dependent manner at a standard dose
of 10 µM (Figure 22). Thus, the miR-10b inhibition mediated by HSP90 inhibitors proved
to be independent of the cancer type.

Finally, using Ingenuity Pathway Analysis, (IPA), we predicted that HSP90 inhibitors
could be regulating the transcription process of miR-10b, through the transcription factor
TWIST (Figure 23). The validation of these predictions could result in future alternative
pathways to target miR-10b.
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Figure 20: HSP90 inhibitors decrease miR-10b levels in BC cells after both 24 and
48 hours of treatment.
The 2 compounds 6-1F and 6-11E (representative the HSP90 inhibitor family), decreased
the levels of miR-10b after two different time-points of treatment: 24 and 48 hours. The
results were consistent in both: MCF-7 and MDA-MB-231 cells.
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Figure 21: HSP90 inhibitors decrease the levels of expression of all three miR-10b
transcripts: primary, precursor and mature sequence
Treatment with compounds 6-1F and 6-11E for 24 hours decreased the levels of pri-miR10b, pre-miR-10b and miR-10b in MDA-MB-231 cells.
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Figure 22: HSP90 inhibitors decrease the levels of miR-10b in vitro in pancreatic
and ovarian cancer cell lines.

Figure 23: Ingenuity Pathway predictions of HSP90 regulating miR-10b transcription
Dosage dependence and MTT assays reveal the inhibitory potency of the “specific
hits”, as well as their half maximal inhibitory concentration of cell death
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Three of the compounds were confirmed as “positive-specific hits” in our screening: 16D-Bosutinib, 6-7C-Clomifene Citrate and 5-6A-Linifanib. For all of them we determined
the potency of the miR-10b inhibition by performing a dosage dependence assay. Using
the previously cloned psiCHECK2 vector, we tested five different concentrations (ranging
from .1µM – 50µM), at two different time-points (24 and 48 hours). Two of the compounds
1-6D-Bosutinib and 6-7C-Clomifene Citrate, increased the luciferase expression 3 to 4
fold after 48 hours of incubation at concentrations as low as .1 and 1µM (Figure 24A and
24C). For both we determined the IC50’s after 24 hours, and 48 hours of treatment with
the compounds in MCF-7 cells: 15.74µM, 8.3µM for compound 1-6D, and 15.2µM, 13.5µM
for compound 6-7C respectively (Figure A and 25C). Similarly, we tested compound 5-6A
and calculated the IC50’s in MCF7 cells, which were 42µM after 24 hours and 9.3µM after
48 hours (Figure 24B). Moreover, compound 5-6A-Linifanib increased the luciferase
expression from 6-fold, at 24 hours, to up to 10-fold, after 48 hours of incubation at a
standard dose of 10µM (Figure 25B).
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Figure 24: Dosage Dependence Assay
The three compounds from the group designated “specific hits” for miR-10b, were tested
for a dosage dependence assay in MCF-7 cells. A total of 5 concentrations were used
(ranging from .1 - 50 uM). The assay was performed at two different time-points: 24 and
48 hours. (A) SMIR 1-6D, (B) SMIR 5-6A and (C) SMIR 6-7C.
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Figure 25: Determination of IC50’s of “specific hits” through MTT Assay
Half maximal inhibitory concentration (for death) was calculated for all three compounds
constituting the “non-specific group”. Experiments were done in MCF-7 cells at 24 and 48
hour time-points. (A) SMIR 1-6D, (B) SMIR 5-6A and (C) SMIR 6-7C.
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Nuclear magnetic resonance (NMR) analysis suggests small molecules 5-6A /
Linifanib directly binds to miR-10b

We proceeded next to determine if the top 3 compounds were validated to target miR10b using NMR. An RNA hairpin corresponding to pre-miR-10b was synthesized to screen
for the RNA binding activity of the compounds by monitoring NMR chemical shift
displacement and resonance broadening in the imino (NH) region of the RNA spectrum.
Peaks in the NH region arise from base pairing and other stable base-mediated intramolecular hydrogen bond interactions. DMSO at 11% was used as a co-solvent for the
compounds and was determined to have minimal effect on the NMR spectra. Although the
size of the RNA molecule and the presence of non-canonical features in the stem of premiR-10b limited the resolution of even the two-dimensional NH spectrum, no spectral
changes could be observed for compounds 1-6D-Bosutinib and 6-7C-Clomifene Citrate
(data not shown). However, compound 5-6A-Linifanib was found to cause small but
reproducible chemical shift changes for peaks in the spectrum, suggesting a specific
interaction between the molecule and the immature miRNA (Figure 26).
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(A)

pre-miR-10b

(B)
DMSO + pre-miR-10b

Pre-miR-10b + 5-6A

Figure 26: 2D NMR of pre-miR-10b and SMIR 5-6A / Linifanib
(A) Precursor sequence of miR-10b used for in vitro transcription. (B) 2D-NMR spectrum
of pre-miR-10b RNA (synthesized in vitro) in 10% DMSO. This spectrum was the control.
(C) 2D-NMR spectrum of pre-miR-10b RNA and SMIR 5-6A / Linifanib. Changes in the
spectrum are pointed out in the arrows.
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In order to narrow down the possible site(s) of interaction and to reduce spectral
complexity, the stem of the pre-miR-10b RNA molecule was divided into three overlapping
segments of approximately 50-58 nt each (designated I, II and III) (Figure 27) and
analyzed individually (for a detailed description of the designed models, refer to AppendixFigure 42). A UUCG tetraloop was used to terminate stem segments I and II and the
UCCG tetraloop native to pre-miR-10b was used to terminate stem segment III. The NH
(1D) spectra of stem segments I and II, which correspond to the base and central regions
of the pre-miR-10b hairpin stem, respectively, were unchanged after addition of 5-6ALinifanib, indicating the compound lacks affinity for these segments (data not shown).
Peaks in the imino and downfield amino regions of the NMR spectrum of stem segment
III, however, are altered by the presence of 5-6A, indicative of binding (Figure 29 – spectra
on the left). Additional peak changes are observed in the base (C6H6/C8H8) region of the
2D 13C-1H HSQC (Heteronuclear Single Quantum Coherence) spectrum (Figure 28). The
regions of sequence overlap between stem segments II and III and the peak perturbations
in the NH and base spectra indicate that binding occurs near the loop end of the RNA
molecule, which is adjacent to nucleotides that are part of the mature 5p and 3p forms of
miR-10b (refer to Figure 27- RNA III).
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RNA I
pre-miR-10b
RNA II

RNA III

Figure 27: Design of oligonucleotide segments of pre-miR-10b
The nucleotide sequence of the pre-miR-10b (miRbase.org), along with the designed
oligonucleotide sequences accounting for three separate regions of the precursor
sequence (as indicated by the selected regions as RNAI, II and III.

DMSO + RNA III

5-6A + RNA III

Figure 28: 2D-NMR spectrum of RNA III and 5-6A / Linifanib
Base regions of the 13C-1H HSQC spectra of RNA hairpin III in the absence (upper) and
presence (lower) of 0.05 mM Linifanib/5-6A. The broad appearance of the peaks in the
spectra is indicative of the dynamic nature of the molecule.
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To further assess the specificity of this interaction, we designed a double mutant of
the stem segment III:

U50C, A62C. These substitutions extend the Watson-Crick

secondary structure to the base of the UCCG tetraloop region. The 1D NH spectrum of
this variant is unchanged by the addition of up to 65 µM 5-6A-Linifanib, indicating that the
compound no longer binds the stem segment III (Figure 29- specta on the right). Overall,
these experiments support a direct interaction between 5-6A-Linifanib with pre-miR-10b
that localizes to the (UG/UGA) internal loop proximal to the cleavage site of Dicer.
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Figure 29: NMR (1D) with RNA segment III of the pre-mIR10b designed
oligonucleotide
The detailed structures of RNAIII is presented (top left panel), with the base paris where
the molecule interacts with it exalted (green circle). The muted version of RNAIIII is
presented (top right panel), with the mutated based paris exalted (green circle). Imino 1H
spectra of stem segment III RNA hairpin in the absence (upper) and presence (lower) of
0.05 mM Linifanib/5-6A. Some of the peaks whose chemical shifts or intensities are altered
are indicated. Imino 1H spectra of a double mutant of the stem segment III RNA hairpin
in the absence (upper) and presence (lower) of 0.05 mM Linifanib/5-6A. The spectra
display no differences indicating Linifanib/5-6A does not interact with the mutant RNA
molecule.
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Computational model of the stem loop region of pre-miR-10b in complex with 5-6A/
Linafinib

With the known chemical structure of compound Linifanib/5-6a (Figure 30A), and a
confirmed interaction to the stem loop region of miR-10b (through NMR), we generated
an in silico model of Linifanib in complex with the UG:AGU internal loop (in stem segment
III) using molecular docking. Figure 30B depicts the possible binding mode for 5-6A within
the stem loop region of pre-miR-10b. Due to the non-canonical base pairing between G51
and G63, the loop region was predicted to bend ~30° with respect to the stem, and A62
formed a bulge which created an extra pocket for the urea phenyl group to bind. The 3amino-indazol moiety, moreover, formed aromatic stacking with G51 base and the amine
group interacted with U61 base through hydrogen bonding. Recognition of this unique
conformation of UG:AGU internal loop is consistent with extended Watson-Crick pairing
and loss of Linifanib binding in the U50C, A62C double mutant.
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(A)

(B)

Figure 30: Predicted molecular docking model of 5-6A / Linifanib and miR-10b
(A Chemical Structure of Linifanib/5-6A. (B) Computational model of the stem loop region
of pre-miR-10b in complex with Linafinib (using rDock). The majority of RNA-small
molecule interactions occurs around UG:AGU internal loop, consistent to NMR data.
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Linifanib /(5-6A) binds to the precursor sequence of miR-10b and inhibit its
maturation process in vitro

To strengthen the biophysically detected interaction between Linifanib/(5-6A) and
pre-miR-10b, we tested the levels of expression of pri-, pre-, and miR-10b mature form, in
the RNA of Linifanib/(5-6A)-treated MCF7-cells. Indeed we found that the levels of the
primary transcript were increased 2-3 fold in the cell model tested. However, the levels of
mature miR-10b decreased significantly. When testing for the pre-miR-10b sequences,
we were not able to detect it in our RNA samples by qRT-PCR (Figure 31).
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Figure 31: Assesment of levels of expression of pri-, pre- and mature-miR-10b
transcripts
MCF7 cells treated with linifanib/5-6A reduce the levels of mature miR-10b sequences (as
tested by qRT-PCR), but increase the levels of its primary transcripts. Pre-miR-10b
sequences were undetectable by this method. These results suggest an interruption of the
miR-10b maturation process.
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Treatment with Linifanib/(5-6A) recovers levels of expression of HOXD10 by
targeting miR-10b without affecting miRNA biogenesis

Additionally, cells were treated with Linifanib, and after 48 hours we verified the
levels of the miR-10b targeted tumor suppressor protein HOXD10. Our results
demonstrated a significant recovery of the HOXD10 levels (Figure 32A). Under the same
conditions we tested for the levels of the two most important proteins required for miRNA
biogenesis and maturation: Dicer and Drosha. With our experiments we demonstrated
that treatment with Linifanib did not reduce the levels of any of these, suggesting miRNA
biogenesis is not significantly altered (Figure 32B).
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Figure 32: Assessment of protein levels after Linifanib treatment (10uM) in MCF7
cells.
(A) Linifanib treatment in MDA-MB-231 cells recovers tumor suppressor target HOXD10.
(B) At 10 µM dosage, Linifanib does not decrease the levels of Dicer, nor Drosha.
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Linifanib/(5-6A) decreases miR-10b levels in MCF7 overexpressing clones

We evaluated the potency of Linifanib in inhibiting the miR-10b in MCF7 clones
overexpressing the precursor sequence of the miRNA. Once again we found that Linifanib
was able to significantly decrease the levels of miR-10b, in conditions where the miRNA
was overexpressed with a fold change of over 1000X.
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Figure 33: MCF7-miR-10b overexpressing clones
MCF7 cells were transfected with a vector containing a constitutively expressed promoter
(labeled pmiR). Downstream of the promoter we cloned the DNA sequence codifying for
pre-mIR-10b. An empty vector was transfected as a control. (A) Transfection efficiency
was monitored through GFP. (B) To test the empty vector vs. pmiR-10b, we extracted
RNA from the cells transfected with both, and performed qRT-PCR for miR-10b levels.
(C) Linifanib treatment after 24 hours reduced miR-10b levels in MCF-7-miR-10b
overexpressing clones.
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Linifanib /(5-6A) binds to the precursor sequence of miR-10b and inhibit its
oncogenic functions in vitro

We also tested for a reversal in the tumor-like phenotype that has been correlated by
overexpression of miR-10b. BC cells with high basal levels of miR-10b were used to
perform a wound healing assay. Alongside we compared Linifanib treatment with
antagomiR-10b. Upon treatment with Linifanib/(5-6A) migration was reduced compared to
solvent/DMSO, and the reduction was comparable to antagomiR-10b.
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Figure 34: Wound healing assay demonstrates that Linifanib decreases migration
In MDA-MB-231 cells, treatment with Linifanib/(5-6A) reduced the migration capabilities
(top panel). The inhibition of migration was comparable to cells transfected with
antagomiR-10b (bottom panel).
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Mir-10b has been demonstrated to affect migration and invasion. Nevertheless it has
not been associated with influencing proliferation. Thus, we tested the effect of
Linifanib/(5-6A) on proliferation in BC cells. We found that Linifanib strongly affects
proliferation at approximately 63% after 24 hours of treatment. We assumed this
mechanism was independent of the miR-10b inhibition, and for further functional assays
where it was relevant, we normalized for proliferation.
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Figure 35: Linifanib inhibits proliferation in breast cancer cells
MDA-MB-231 cells treated with Linifanib/(5-6A) reduced their proliferation in 63% after
24 hours.
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We then proceed to perform migration and invasion assay in BC cells with inserts
coated with either gelatin or collagen. Cells treated with Linifanib markedly inhibited
migration as well as invasion in BC cells. Our results were normalized for proliferation (by
subtracting the 63% of the effect in cells treated with Linifanib), and still both (migration
and invasion) were reduced significantly.
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Figure 36: Linifanib/(5-6A) treatment decreases migration and invasion in BC cells
Linifanib/(5-6A) treatment decreases migration and invasion in MDA-MB-231 cells after
24 hours of treatment.
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Linifanib decreases miR-10b levels in hepatocellular and colorectal cancer cells in
vitro

We hypothesized that the inhibition of mIR-10b would be consistent among different
cancer cell lines. In this regard, we opted to test cell lines of lung, liver and colorectal
cancers. We selected these cancer types in particular because Linifanib was used in
clinical trials for all of them. After a 24 hour treatment, we observed that the reduction in
miR-10b levels was consistent among different cancer types such as: non-small cell lung
cancer (NSCLC), HCC, and CRC (Figure 33).

Colorectal cancer
DLD-1

Hepatocellular carcinoma
Hep-G2

1 .0

**

0 .9

Fold Change in
miR-10b levels

0 .8
0 .7
0 .6
0 .5

**

0 .9
0 .8
0 .7
0 .6

O

u

u

o

o

h

4

4

2

2

S

S

M

M

D

D

rs

rs

0 .5
O

h

Fold Change in
miR-10b levels

1 .0

Figure 37: Linifanib decreases miR-10b levels in HCC and CRC cells in vitro
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CHAPTER IV: Discussion
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Summary

Breast cancer is the second most common cancer in the world (following lung
cancer), and the leading cause of cancer death in women [162]. Its burden exceeds all
other cancers and the incidence rates are consistently increasing [163]. One of the main
reason for this is the fact that the heterogeneity of BC tumors makes them a challenging
one to treat [164].

Regarding their molecular characterization, hormonal therapy has improved the
outcome of patients with ER/PR positive tumors [165]. Herceptin has also significantly
influenced treatment response and overall survival in patients with HER2 positive tumors
[166]. However, taken together, these parameters have not achieved the realization of an
extremely effective individualized targeted therapy for patients, and resistance to therapy
continues to be frequently encountered in the clinic [12, 167, 168]. Furthermore, molecular
subtypes such as TNBC tumors are not efficiently treated with the approaches above
mentioned, and the prognosis of these patients is significantly low [169, 170]. Hence, new
systemic therapies are desperately needed, and the study and development of
personalized cancer therapy, represents a strategic approach in aiming to overcome
therapeutic inefficiency and/or resistance [171].

MiRNAs are a type of non-coding RNA transcript that can regulate oncogenic
processes, and thus, they are considered crucial elements in fields such as: “personalized
cancer therapeutics”. MiRNAs-based research throughout the years has emphasized that
specific miRNAs are up- or down-regulated, concurrently, in cancer [73]. Their
dysregulation, results in the activation/inactivation of oncogenes or tumor suppressor
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genes respectively [73]. Therefore, from a therapeutic point of view, miRNA targeting
possesses anti-cancer potential, based on the fact that the cancer phenotype can be
changed by targeting miRNA expression. Furthermore, miRNA signatures and profiles in
BC have been thoroughly studied in the past, and strong evidence has already been
established regarding their therapeutic potential [3, 172, 173]. In this regard, the
development of a therapy to target specific oncogenic mIRNAs represents a significantly
important approach for new treatment options.

In this study, we decided to focus on testing small molecules that have undergone
clinical trials or that are already FDA approved (with adequate pharmacokinetic/dynamic
properties for in-human delivery), to target microRNAs. We hypothesized that alreadyavailable small molecules could bind specific RNA motifs and inhibit the function of
oncogenic miRNAs. If proven effective, this would expand their applicability in the clinic,
greatly accelerating the lengthy process of drug discovery [100]. In our approach, we
combined techniques such as bioinformatics, non-coding RNA technologies, chemical
compound library screening and structural chemistry, with the aim of identifying oncogenic
miRNAs to target in BC. We also designed and validated a step-wise approach that can
be used to discover small molecule compounds that directly bind oncogenic miRNAs and
inhibit their functions in vitro.

The key finding from this study is that Linifanib, the receptor tyrosine kinase
inhibitor, directly interacts with the precursor sequence of miR-10b (a known oncogenic
miRNA in BC). More so, we found that the interaction of Linifanib with the miRNA results
in the recovery of tumor suppressor proteins (e.g. HOXD10) and can reverse the cancer
phenotype in vitro.
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Overall, we have identified a number of assays with high sensitivity and specificity,
which allow an adequate identification of molecules that can target oncomiRs. Our
techniques are reproducible and applicable to a broad range of other types of cancer, or
to any other pathology that involves miRNA overexpression.
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Small molecule compounds targeting miRNAs

Compared to the currently known treatment regimens, miRNA-based therapeutics
offers the advantage of targeting multiple genes with different roles within a cancer
network. Previous strategies have involved the use of oligonucleotides or viral-based
constructs; however, early clinical trials have showed that their delivery can be ineffective
or toxic [100]. Recent focus regarding miRNA-based therapeutics has centered on the
possibility of using small molecule inhibitors to target miRNAs directly. Nevertheless, to
date, very few studies have successfully been able to find small molecules to target
oncomirs in an effective manner. Herein we review the most important findings regarding
small molecule compounds targeting miRNAs.

The first screening assay to detect small molecules targeting miRNA processing
was done by Davies and colleagues in 2006. Using pre-let-7 RNA from Drosophila
melanogaster, they developed a doubly-labeled pre-miRNA beacon with a fluorescent
emitter and quencher able to detect Dicer processing (hydrolysis) through fluorescence
emission. In this way, they established the first homogeneous fluorescence assay to
detect miRNA inhibitors [106, 107]. However, their main focus was to find molecules that
targeted the miRNA biogenesis process (in a non-specific way).
In 2008, a study done by Gumireddy and colleagues; the group claimed to have
found an inhibitor of a miRNA [104]. They selected miR-21 as the target miRNA because
of its known tumorigenic properties in cancer [38, 69, 174, 175]. They then developed a
lentiviral reporter construct with the miR-21 target sequence, downstream of a luciferase
reporter gene. Diazobenzene, was found as positive hit in the study; however a thorough
analysis revealed that the compound actually targeted the transcription of the miR21coding gene [104]. In another similar study, Young and colleagues developed a project
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focused on targeting miR-122, a miRNA crucial for hepatitis C virus (HCV) infection and
replication [176]. A luciferase based psiCHECK-2 reporter plasmid was used to screen for
SMIRs [176], and 2 hits were identified. Nevertheless, both of the compounds targeted the
transcription of the miRNA-coding gene upon treatment (againproving to have an indirect
mechanism of inhibition) [176].

Following this, Watashi and colleagues developed a very extensive screening for
SMIRs that could target oncomiRs -93 and -130b [177]. Collectively their results
suggested that one of their compounds reduced pre-miRNA association with Dicer, while
the other reduced the miRNA association with AGO2 (enzymes important for miRNA
biogenesis) [90,[177] . Even though both treatments demonstrated to reverse the cancer
phenotype in vitro, their mechanisms of action were indirect ones [177]. In a similar
approach, Bose et.al; screened for SMIRs against miR-21, using a luciferase-based
reporter was used (pEZXMT01 plasmid) with the complementary 3’UTR sequence [108].
In the screening, Streptomycin was found as a hit inhibitor in a BC model in vitro, by
interfering with the Dicer processing of the miRNA [108]. However, when testing the levels
of additional miRNAs to determine the specificity of the inhibition, out of a total of 10 tested,
miR-27a was proven to be downregulated as well [108].

The idea of targeting miRNAs with small moelcules continued expanding in 2013
when Bose and colleagues used a fluorescent probe (Refer to Figure 7A) to screen a total
of 14 compounds, and test if any of them inhibited miR-27a, a miRNA proven to be overexpressed in several cancer types [103]. They found that a set of them inhibited Dicercatalyzed miR-27a maturation [103]. Their high-throughput beacon-based assay
compared favorably to other previously described methods, as it proved to be costeffective, sensitive and robust. Unfortunately their results were validated in vitro only in 1
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cell model (which doesn’t rule out that the compound-mediated inhibition is cell-specific
manner)

With the aims of achieving SMIR against miR-21 with a higher specificity, Shi and
colleagues designed an in silico technique [101]. By using the three-dimensional structure
of the Dicer binding site on the pre-miR-21, they conducted an in silico screening of 1990
compounds to find molecules that could block miR-21 maturation using MC-Fold/MC-Sym
and Auto Dock programs [101]. Through this method, they identified a SMIR termed
AC1MMYR2, which blocked the ability of Dicer to process the pre-miR-21. Its potency was
tested and validated in vitro [101]. More so, the compound demonstrated a decrease in
tumor growth, invasiveness, and metastasis, thereby increasing overall host survival in
vivo [101]. Their approach was very successful in the fact that they actually managed to
thoroughly evidence a reversal of the cancer phenotype. Nevertheless, 5/11 alternative
miRNAs tested, were also significantly reduced upon treatment [101]. More so, they did
not perform assays to demonstrate a direct interaction between the structure of the
molecule and the pre-miR-21.

On another note, two important miRNAs in gastric cancer: miR-372 and miR-373,
were also the focus of investigation when searching for SMIR candidates. In their
screening, Vo and colleagues reported the first example of multimodal RNA ligands aiming
to inhibit the biogenesis of oncomiRs [178]. The multimodal ligands were composed of an
artificial nucleobase design

that recognizes the pre-miRNA, and an aminoglycoside

known to interact in a potent manner with stem-loop RNAs (with high affinity) [178]. Some
of their multimodal ligands inhibited Dicer precursor cleavage by binding to these stemloop structured RNAs [178]. More so, one of their hits proved to be an efficient miR-372
and -373 inhibitor in vitro, demonstrating a dose dependent decrease of the miRNAs [178].
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Their approach demonstrated to be successful for targeting these particular oncomiRs;
however, they identified a significant decrease in the levels of at least 3 other oncogenic
miRNAs as well, upon treatment.

Recently, a research group developed “Inforna”, a novel approach that was
validated to design lead compunds that target miRNA precursors previously identified
through sequencing and functional studies [179]. Initially they downloaded the sequences
of all the miRNA hairpin precursors in the human transcriptome, and subsequently, their
secondary structures were predicted in silico. Inforna created the output of the targetable
motifs in each RNA, and the corresponding lead small molecules that could potentially
bind them [179]. Their results showed a strong interaction between benzimidazole and the
precursor sequence for miR-96 [179]. Unfortunately these results were only validated in
vitro in a single cell line model.

Finally, Murata and colleagues studied the synthesis and structure–activity
relationships of xanthone and thioxanthone derivatives as fluorescent indicators of
interactions between small molecules and RNA sequences [180]. In their study they
demonstrated that the xanthone and thioxanthone derivative X2S-N, N-diMe inhibited
premiR-29a maturation in a specific manner by binding to the nucleotides that form part
of the internal loop/bulge (but not by any interaction with the processing enzyme Dicer)
[180]. However, the off target effect of this compound (inhibition of other miRNAs) was not
investigated [180].
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Current challenges

Compared to proteins, miRNAs (and all RNA molecules in general) have been
quite neglected as promising drug targets. This is mostly due to the absence of defined
molecular structures for the majority miRNAs; a fact that increases the difficulty of
predicting which inhibitors can bind them. However, the truth of the matter is that miRNAs
are indeed “druggable”, due to the formation of stem loop in precursor sequences and
bulges in miRNAs [88]. Their structural features not only enlarge the major groove for drug
entry, but also partially disclose the internal bases, scattering the local electronegative
distribution [88]. These advantages suggest that it would be feasible to target them with
small molecules.

Only a handful of studies have been published over the last 10 years, regarding
small molecules targeting miRNAs. Although advancements in screening techniques and
validation of targeted hits have been seen, there are still weaknesses in the studies
performed, and thus several challenges to overcome. In view of this, we aimed to identify
the most important ones, to determine what changes could be implemented when
screening for SMIRs. Altogether, our primary endpoint was to find drugs that could be
specific by targeting oncomiRs directly; and as the initial step when doing so, we
determined to address several flaws (which will briefly be discussed).

Firstly, we determined that it is important to test if our compounds cause any
alterations of the miRNA biogenesis pathway machinery. The reason for this is because
when the concept of targeting miRNAs with small molecules began, one of the ideas was
targeting their maturation process in cells; and several research groups performed
screenings focusing on finding inhibitors of the miRNA biogenesis pathway. However, this
approach

proved

inefficient,

due

to

the
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fact

that

by

inhibiting

miRNA

biogenesis/maturation, the expression of all miRNAs was targeted / affected. MiRNAs
crucial for cellular homeostasis could be altered in this manner, not to mention many tumor
suppressor miRNAs would be affected as well. Thus, we determined it was crucial to test
if the small molecule treatments have an effect in elements (such as enzymes like Dicer,
Drosha) that are required for the processing of miRNAs (their maturation process).

Secondly, but on the same line, we believe that it is very important to determine if
treatment with the small molecules affects the transcription of the miRNA-coding gene (of
our miRNA of interest). This could be done by testing changes in methylation of promoter
sequences of the specific miRNA-coding gene; or more easily, by verifying the levels of
primary and precursor sequences (along with the mature miRNA itself). The later because
when small molecules target transcription, the levels of all three miRNA transcripts are
decreased upon treatment.

On a separate note (thirdly), the levels of additional miRNAs should be tested
under the same conditions done in which the screenings are performed. Unfortunately in
several of the studies done to date, the levels of additional miRNAs were not tested after
treatment, a fact that doesn’t allow a “prediction” of the degrees of specificity of the
inhibition. More so, those that claim to do so “randomly” select miRNAs to test in addition
to their target one, but their selections include miRNAs that are not considered oncogenic,
or that have even been validated to be tumor suppressors (not oncomiRs that might have
similar functions in cancer). Additionally (fourthly), in vitro models should include at least
two different cell lines with different properties, in order to demonstrate that the small
molecule inhibition is not cell-specific, but miRNA-specific.

Finally (fifthly), one of the most significant weaknesses of the SMIR studies to date
is that none of them have demonstrated enough evidence describing a direct interaction
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between a small molecule and the miRNA of interest. The closest to it, was when a
research group demonstrated through an in silico-predicted docking model, that the small
molecule AC1MMYR2 bound to the pre-miR-21 and blocked its maturation [101].
However, their models were not validated through techniques such as nuclear magnetic
resonance or mass spectroscopy; and thus there is a level of uncertainty regarding the
interaction itself. This uncertainty arises due to the fact that miRNAs (the majority) are not
available as a crystal structure, and thus the 3D computerized models actually use a
prediction of their crystal structure when searching for candidates molecules that can
target them. In other words, they are actually developing a model that is based on: “a
prediction of a prediction”. Because of this, very few molecules identified through
computerized programs as: “likely to bind a specific miRNA”, have an actual interaction
that is able to be validated in vitro an in vivo. From this perspective, the biggest challenge
is not quite to find a compound that evidently inhibits an oncogenic miRNA, but more so
proving that it does so through a direct interaction.

To this extent, we believe that a specific SMIR:miRNA interaction could be thoroughly
evidenced by addressing all of the mentioned criteria. In summary, these criteria include
proving that the small molecule does not alter the following: miRNA biogenesis
/processing, the levels of expression of additional oncogenic miRNAs, or the transcription
of the specific miRNA-coding gene. To achieve an even more precise SMIR:miRNA
interaction, results should be validated in at least two cellular models (with different
characteristics. Additionally, it is crucial to demonstrate a direct interaction through
structural analysis such as crystallography or nuclear magnetic resonance.

Small molecule screening for SMIRs targeting miR-10b or miR-21
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Chemical compound libraries offer the advantage of allowing screenings of known
therapeutic agents, the majority of which have been tested in pre-clinical and clinical trials,
some even approved by the FDA for different diseases. As a result of screening libraries
of chemical compounds, new potent inhibitors have been discovered for and array of
diseases such as infections, neurological disorders and cancer [181-183]. In this study,
as proof of concept, we used approximately 450 compounds from a chemical library of
known small molecule inhibitors to test their ability to interact with, and inhibit oncomir-10b
or -21. The results of our screening demonstrated that using a combination of assays with
high specificity and sensitivity, we were able to find a small molecule that directly interacts
with, and inhibits an oncogenic miRNA (miR-10b).

Role of heat shock protein 90 in regulating the transcription of miR-10b
As part of our screening design, we performed a series of assays to test if the small
molecules where specific on their miRNA inhibition. As a result, we eliminated compounds
that altered the levels of expression of any of the oncogenic miRNAs tested after treatment
(besides the targeted one). Interestingly we found a group of compounds belonging to the
same family of inhibitors: inhibitors of heat-shock protein 90. Even though these inhibitors
proved to downregulate two or more miRNAs in a non-specific manner, they demonstrated
to inhibit miR-10b very potently (even though they had very different molecular structures).
More so, they demonstrated to decrease the levels of all three: primary, precursor and
mature miR-10b transcript.
With the aims of establishing a link between HSP-90 inhibitors and decrease in
miR-10b levels, we used Ingenuity Pathway Analysis, (IPA), to predict the correlation
between HSP90 inhibitors and miR-10b. In our prediction we found that HSP90 enhances
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the activity of HIF1-alpha, which promotes both TGFB4 and STAT3. Furthermore, TGFB4
and STAT3 were both predicted to enhance TWIST, a transcription factor known to
increase the expression of miR-10b (Figure 23).
In the past, several studies had already proven to link several of these
relationships, although (to our knowledge), no one has validated the complete pathway
from HSP90 to miR-10b. For example, for years a direct correlation between HSP90
protein and HIF1-alpha has been known. A research group in 1999, demonstrated
thoroughly for the first time, that Hsp90 activity is essential for HIF-1 activation, by
demonstrating that using the HSP90 inhibitor geldanamycin, they achieved potent
inhibition of HIF-1alpha [184]. Since then, several research groups have validated the
interaction between both proteins extensively [185, 186].
Regarding elements further down the pathway, it has been demonstrated that
TGFβ triggers SMAD-dependent induction of 2 important transcription factors: SNAIL1
and TWIST [187]. Additionally, several studies have indicated that STAT3 transcriptionally
induces Twist, which plays an important role in promoting migration, invasion, and
anchorage-independent growth [188, 189]. Finally, the transcription factor TWIST has
been thoroughly demonstrated to increase the transcription of miR-10b, which is also
predicted in our IPA model (refer to Figure 23) [63, 64] .
Unfortunately, from the correlations of our IPA-predicted pathway there have not been any
studies that validate hif1-alpha as a regulator of TGB4 or STAT3. Interestingly STAT3 has
indeed been validated to regulate HIF1alpha expression [190, 191]. Thus, the majority of
the predictions from the IPA model have been individually proven in the past; which
strongly suggest the pathway has a high probability of being validated altogether. The
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confirmation of these predictions could lead to alternative pathways to target in diseases
where miR-10b is an overexpressed miRNA contributing to pathology.

Small molecule Linifanib targets miR-10b through a direct interaction
In our screening, we identified 5-6A-Linifanib as a specific SMIR which blocks miR10b processing by binding to the precursor sequence near the stem loop region. More so,
we validated the direct interaction thoroughly using NMR techniques to assess the
molecular dynamics of the small molecule in the presence of pre-miR-10b.

Previous studies
Linifanib is a novel potent inhibitor with selectivity for the VEGFR and PDGFR
family of receptor tyrosine kinases (RTKs) [63, 64, 192]. In nonclinical in vivo studies,
Linifanib demonstrated potent inhibition of tumor growth in xenograft models of over 15
different tumor types [75]. In preclinical studies, it was also proven to have antitumor
activity as a single agent or in combination with known chemotherapies [77] . To date,
Linifanib has proven to be clinically active in patients with an acceptable safety profile;
therefore, a total of 18 clinical trials have been initiated in diseases including solid tumors
such as BC [193], CRC, non-small cell lung cancer (NSCLC) [194], renal cell carcinoma
(RCC) [195], but to a more significant extent in HCC [77]. Specifically, in a phase 1 clinical
trial, it demonstrated potent antitumor effects as a single-agent in patients with refractory
solid malignancies [196]. More so, Linifanib has also shown antitumor activity in phase 2
studies in patients with NSCLC, HCC or RCC [194, 195].
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The most significant studies in which Linifanib has been used as a therapeutic
agent have been performed in HCC. Remarkable results have been achieved (several
years ago) in both: nonclinical, and preclinical trials; and thus, it became evident that
linifanib could be considered a potential new threatment for patients HCC [75, 77]. In order
to do so, linifanib was compared with the standard of care treatment for patients with HCC:
the multitargeted tyrosine kinase inhibitor sorafenib, which blocks the activity of Raf
serine/threonine kinase isoforms, VEGFR-2 and -3, PDGFR β, c-KIT, FLT-3, and RET. By
doing so, sorafenib inhibits tumor angiogenesis and cell proliferation [26, 27, 197-201]. It
was chosen as standard of care for patients with advanced HCC based on results from 2
large randomized trials, both which showed an improvement in overall survival (OS)
compared to placebo [200].

In order to compare their efficiencies, both inhibitors were compared in (2014), in
a randomized phase 3 trial in patients with advanced HCC [200]. The primary endpoint of
the trial was comparing OS between treatments of linifanib vs. sorafenib. The results of
the trial demonstrated that there was a slight difference in the median OS of patients
treated with Linifanib vs Sorafenib, of 9.1 months and 9.8 months respectively [200].
However these results were not statistically significant. More so, regarding the secondary
outpoints of the study: the time to progression (TTP) of patients receiving linifanib were
significantly longer (P=.001), and the objective response rate (ORR) of these patients was
also significantly higher (P=0.018) [200]. Furthermore the response rates (RR) for linifanib
compared favorably to previous phase 3 trials of sorafenib in advanced HCC (13% vs
6.9%) [198, 199]. Nevertheless, improvements in all these did not translate into increase
in OS. Thus, the study failed to achieve its primary endpoint, and sorafenib continues to
be the treatment of choice for these patients.
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New mechanistic role of Linifanib
In our screening we observed and validated a new mechanistic role for Linifanib:
the direct inhibition of miR-10b. In BC models we observed that Linifanib decreased the
levels of miR-10b, and the sensitivity of the inhibition was consistent among three different
cell line models, suggesting that the effect was independent of the molecular
markers/histological tumor subtypes. By restoring the levels of the tumor suppressor target
HOXD10, Linifanib decreased invasion and migration of BC cells. Since previous studies
have demonstrated both in vitro and in vivo, that silencing of miR-10b markedly
suppresses formation of BC metastasis [47, 63], linifanib represents an attractive agent to
target BC disease progression (and spread) by inhibiting, the “oncmiR-10b addiction” of
these tumor types.

The fact that linifanib physically interacts with, and inhibits miR-10b, opens up a window
of therapeutic opportunities, not only for BC, but for other cancer types as well. As
previously described, linifanib treatment has been tested (and is currently being tested) in
several clinical trials, of cancer types such including CRC, NSCLC and HCC. Interestingly,
all of these cancer types have been proven to worsen upon increased miR-10b
expression. For example, high level miR-10b expression was found to be significantly
associated with high incidence of lymphatic invasion and poor prognosis in CRC patients
and has been shown to confer resistance to chemotherapeutic agents in vitro [202].
Furthermore, in NSCLC miR-10b expression levels are significantly positively correlated
with the tumor stage and regional lymph node involvement, and patients with higher levels
of miR-10b have significantly poorer survival compared to those with lower expression of
this miRNA [203, 204]. More importantly, miR-10b is highly expressed in metastatic HCC
tissues inducing invasion and migration; and patients with higher miR-10b expression
have significantly poorer OS [137, 205].
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The evidence of miR-10b having a crucial role in cancer types for which linifanib
has been explored as a possible treatment option, suggests that there might be a link
between overexpression of miR-10b and linifanib treatment inefficiency. Supporting this
are the results of the phase 3 randomized clinical trial evaluating linifanib treatment in
patients with advanced HCC. Results demonstrate that initially (first 3/4s of the treatment
period) linifanib proofs more effective than the standard of care (with a higher progression
free probability) compared to the standard treatment (sorafenib). Additionally, OS seems
to be equal between both treatments during the initial 3/4s of the treatment period, and
only separates from the standard-of-care treatment at the very end of the treatment period.
These results, alongside the fact that miR-10b expression increases upon metastatic HCC
and is associated with decreased OS, suggest that high levels of miR-10b can overcome
the “miR-10b targeting” by linifanib and contribute to disease progression/relapse. Thus,
in clnical trials of patients with advance HCC, where linifanib did not impove the OS
compared to Sorafenib, we speculate that poor responders to linifanib are most likely
patients with enhanced miR-10b overexpression to begin with, or developed along a
period post-treatment to overcome the effect of linifanib.

In this regard, we believe that the fact that Linifanib inhibits miR-10b (along with its known
targets), could be contributing to define the therapeutic efficacy of preclinical models and
clinical trials of different cancer types, and that the combination of linifanib with additional
agents could increase the positive outcomes of cancer patients. To achieve this (and as
a subsequent translational approach of our findings), we believe that by evaluating the
chemical functional groups of Linifanib that target motifs of the pre-miR-10b, we will have
a basis to develop a series of small molecules with variable levels of affinity towards RTKs,
and more towards binding miR-10b. We predict that SMIRs against miR-10b could offer
potential therapeutic benefits in additional tumor types that have been proven to be
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oncomiR-10b addictive, not only breast but also, HCC, NSCLC, CRC, pancreatic cancer
and glioblastoma [160, 161, 206]. Furthermore, our study validates the fact that by
upscaling screenings such as this one to a high throughput manner, many potential SMIRs
could be discovered and used as targeted therapy for cancer patients.

110

CHAPTER V: Future Directions
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Structure analysis of small molecule inhibitors of miRNA (SMIRs) maturation

MiRNA precursor sequences have array of internal loops and non-canonical pairings
in combinations that are unique for each miRNA, offering target specificity. However,
structural based hit discovery highly relies on precise high-resolution structures, and with
miRNAs, their inherent flexibility limits the number of structures available (approximately
1% in Protein Data Bank). Only a handful of structures have been elucidated for miRNA
fragments and none of them are in complex with small molecules. Furthermore, in silico
modeling techniques for RNAs have not yet reached the capacity of those for protein
targets. Limitations on direct structure determination and computational modeling have
significantly restricted drug discovery efforts against RNAs.

One of the approaches to overcome these challenges and barriers is developing an
integrated platform for miRNA structural studies and inhibitor discovery by combining
cutting-edge in silico modeling and direct structure methodologies. Dedicated
computational methods are in the need of being employed, in order to build initial structure
models of miRNAs. Validation of these methods through solution NMR is critical in order
to investigate their conformational dynamics, and generate an ensemble of structures that
accurately reflect their conformational distributions.
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Medicinal synthesis and testing of newly synthesized compounds to establish
structure-activity relationship and drive lead optimization

Derived knowledge from miRNA structural studies can be used to design new more
potent derivatives. Each of the scaffolds can be synthesized followed by experimental
evaluations for biological activity in vitro and in vivo. The process of lead optimization
would most definitely be a synergistic and iterative process involving modeling, synthesis,
and biological testing.

To complement the optimization of linifanib (5-6A) (or other prospective compounds),
a structure-based strategy can be implemented in order to identify compounds specific for
non-Watson-Crick features in the stem of pre-miR-10b (Figure 26C). Heteronuclear NMR
spectroscopy can be used to generate ensembles of structures that accurately reflect the
conformational distribution sampled by the centrally located C-A and A-A mismatches and
the GUAA/AAAC internal loop at the base of the hairpin. RNAs I and II (Figure 27) , which
contain these features, can be used. These data could serve as the input for structurebased virtual HTS hit identification and alternative SMIR design.
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In vivo studies to characterize optimized lead compounds

Expanding the pharmacokinetic (PK) experiments would be an important path to
continue directing this project. Studies including absorption and distribution of the
administered drug, as well as the rate at which a drug action begins, the duration of the
effects, the chemical changes of the substance in the body (e.g., by enzymes), and the
effects and routes of excretion of the metabolites of the drug are significantly important.
PK studies should be done using only rodent at single, multiple, or cassette dosing. They
should

include

preclinical

non-compartmental

pharmacokinetics,

compartmental

pharmacokinetics, ascending dose (assessment of dose proportionality), repeat dose
(assessment of multiple-dose linearity), etc.

The toxicity of the modified compounds should also be assessed through gross
observation, blood chemistry, and selected tissues taken for histological examination.
Concentrations should be determined through techniques such as high performance liquid
chromatography. The plasma area under the concentration time curve of the molecules
should be determined, as well as other pharmacokinetic parameters, including half-life
(T1/2), apparent volume of distribution (Vd), clearance (Clint), etc.

Drug physicochemical properties are critical for their stability, formulation,
bioavailability, and other pharmacokinetic behavior. Several pharmacodynamic properties
are also important to be studied to determine the gastrointestinal absorption and the
compound’s oral bioavailability [207]. Lipophilicity, is also a key determinant of the
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pharmacokinetic behavior of drugs that should also be assessed , as well as the
compound’s chemical stability [208].

Completion of PK and pharmacodynamic studies, would clearly lead to assessing the
anti-tumor activity of lead compounds in vivo independently and in combination with either
anti-miR10b, LNAs or with standard chemotherapy regimens. The main objective of such
studies would be to investigate in vivo antitumor activity of our lead compound against
breast tumor xenografts in scid mice. The primary endpoint of the experiments would be
overall survival (OS), defined as the time from the malignant cells administration to the
time of death or to the time of sacrifice. By targeting overexpressed miR-10b with a specific
SMIR, we expect that apoptosis will be induced, and more so, invasion and migration will
be reduced. We believe that altogether the anti-tumor activity will be significant in animal
studies.
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Table 2: Oligonucleotide design for Psi-CHECK2 vector inserts

miRNA / Mature sequence

Designed oligonucleotides
#1

hsa-miR-10b

5' - CGCAGTAGAGCTCTAGTCACAA
ATTCGGTTCTACAGGGTAGTTT - 3'

UACCCUGUAGAACCGAAUUUGUG

#2

5' - AAACTACCCTGTAGAACCGAATT
TGTGACTAGAGCTCTACTGCGAT - 3

#1
hsa-miR-21

5' - CGCAGTAGAGCTCTAGTTCAAC
ATCAGTCTGATAAGCTAGTTT - 3'

UAGCUUAUCAGACUGAUGUUGA

#2

5' - AAACTAGCTTATCAGACTGATGT
TGAACTAGAGCTCTACTGCGAT - 3'

Nomenclature: 5’ SgfI site – linker – miR-10b binding site – PmeI site– 3’

Table 3: Taqman Real-Time PCR Assays

miRBase ID

Assay Name

Assay ID

Catalogue #

hsa-miR-10b-5p

hsa-miR-10b

002218

4427975

hsa-miR-21-5p

hsa-miR-21

00397

4427975

n/a

U6 snRNA

001973

4427975

miRBase ID

Stem loop accession #

Assay ID

Catalogue #

hsa-miR-10b

MI0000267

Hs03302879_pri

4427012

hsa-miR-21

MI0000077

Hs03302625_pri

4427012
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Table 4: Primers designed for this study

Primer

Type:

Sequence:

Experiment:

Forward

CCCTGTAGAACCGAATTTGTG

RT-PCR of premiR

name:
pre-miR-10b

sequence
pre-miR-10b

Reverse

TGAAGTTTTTGCATCGACCA

RT-PCR of premiR
sequence

pre-miR-21

Forward

TGTCGGGTAGCTTATCAGAC

RT-PCR of premiR
sequence

pre-miR-21

Reverse

TGTCAGACAGCCCATCGACT

RT-PCR of premiR
sequence

U6-

Forward

CTCGCTTCGGCAGCACA

normalizer
U6-

gene (control)
Reverse

AACGCTTCACGAATTTGCGT

normalizer
pre-miR-10b

RT-PCR reference

RT-PCR reference
gene (control)

Forward

CGGGATCCTCCTTGGGATGGA

Clone-premiR-DNA
coding region

pre-miR-10b

Reverse

CGGGATCCAGGAAAAGCTGCT

Clone-premiR-DNA
coding region

pre-miR-21

Forward

CGGGATCCGTTTTTGATTGAA

Clone-premiR-DNA
coding region

pre-miR-21

Reverse

CGGGATCCTTTATTTGTGGTC

Clone-premiR-DNA
coding region
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Table 5: Antibodies

Antibody Name

Manufacturer

Catalogue ID

Vinculin

Santa Cruz

sc-7649

HOXD10

Abcam

ab90704

Dicer

Cell Signaling

5325

Technologies
Drosha

Cell Signaling

3364S

Technologies
α-Tubulin

Sigma Aldrich

T9026

Table 6: Molecular Structures of the Heat Shock protein-90 inhibitors included in
the study
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MCF7

Fold Change R/F

6

A.
B.
C.
D.

4

Vector + target sequence for miR-10a
A + antagomiR-10a
A + pre-miR-10a
A + antagomiR-scramble

2

0
A

B

C

D

Figure 38: Luciferase-based reporter for miR-10b levels tested in the presence of
different levels of miR-10a
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Figure 39: Luciferase-based screening for miR10b: Plates 1-6.

Fold Change Renilla/Firefly

Plate 1

Small Molecules
(Columns represent groups of 8 molecules)

Fold Change Renilla/Firefly

Plate 2

Small Molecules
(Columns represent groups of 8 molecules)
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Fold Change Renilla/Firefly

Plate 3

Small Molecules
(Columns represent groups of 8 molecules)

Fold Change Renilla/Firefly

Plate 4

Small Molecules
(Columns represent groups of 8 molecules)
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Fold Change Renilla/Firefly

Plate 5

Small Molecules
(Columns represent groups of 8 molecules)

Fold Change Renilla/Firefly

Plate 6

Small Molecules
(Columns represent groups of 8 molecules)
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Figure 40: Luciferase-based screening for miR21: Plates 1-6.

Fold Change Renilla/Firefly

Plate 1

Small Molecules
(Columns represent groups of 8 molecules)

Fold Change Renilla/Firefly

Plate 2

Small Molecules
(Columns represent groups of 8 molecules)
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Fold Change Renilla/Firefly

Plate 3

Small Molecules
(Columns represent groups of 8 molecules)

Fold Change Renilla/Firefly

Plate 4

Small Molecules
(Columns represent groups of 8 molecules)
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Fold Change Renilla/Firefly

Small
Molecules
Plate
5
(Columns represent groups of 8 molecules)

Small Molecules
(Columns represent groups of 8 molecules)

Fold Change Renilla/Firefly

Plate 6

Small Molecules
(Columns represent groups of 8 molecules)
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Figure 41: Luciferase-based screening for miR21: Plates with excluded outliers.

Fold Change Renilla/Firefly

Plate 1

Small Molecules
(Columns represent groups of 8 molecules)

Fold Change Renilla/Firefly

Plate 3

Small Molecules
(Columns represent groups of 8 molecules)
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Fold Change Renilla/Firefly

Plate 5

Small Molecules
(Columns represent groups of 8 molecules)
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Figure 42: Detailed design of oligonucleotide sequences for NMR studies.

The nucleotide sequence of the pre-miR-10b (miRbase.org). Three guanine nucleotides
were added to the 5’ end to facilitate in vitro transcription. The mature 5p and 3p miR-10b
sequences (capitalized and italicized) are released after processing by Dicer. Boxed
regions show segments of the stem that were prepared as three separate RNA hairpins.
Helical segments I (dotted) and II (dashed) were capped by UUCG tetraloop sequence to
facilitate folding of the RNA molecules. The UCCG loop sequence of segment III (solid)
was left unchanged. Cross-strand pairing in the terminal loop exends the helix and
introduces an internal loop (UG/UGA).
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